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Abstract 
ERAP1 is an aminopeptidase that is a component of antigen processing. To 
distinguish the role of ERAP1 from homologs ERAP2 and IRAP, I identified three 
specific ERAP1 inhibitors via a high-throughput screen. These compounds inhibit 
hydrolysis of a decamer peptide, and some inhibit ERAP1 in a cellular assay. 
These inhibitors enable dissection of ERAP1 mechanism. ERAP1 has been 
crystallized in two conformations: open and closed. I collected SAXS data on 
ERAP1 in the presence of various inhibitors. ERAP1 adopts an open 
conformation in solution, but some inhibitors stabilize the closed form. Compound 
3 docks to a distal pocket 28Å from the active site zinc, while DG013 and DG014 
bind to the active site. This distal pocket is an allosteric activation site, and 
allostery is mediated by stabilizing the closed state. I also identified an 
intermediate step in substrate binding where helix 4a becomes ordered while 
ERAP1 maintains an open conformation. Helix 4a then rotates and engages 
substrate when ERAP1 closes. The nonsynonymous SNP rs30187 at position 
528 (Lys/Arg) subtly alters ERAP1 activity in vitro and correlates with disease 
incidence. Position 528 forms a conformation-dependent electrostatic interaction 
with Glu913 in the closed structure. The energetic contribution of this interaction 
is stronger for Lys528 than Arg528. Inhibitors that induce closing are more potent 
for Lys528 than Arg528. I propose a model where either helix 4a stabilization or 
allosteric site occupancy shift the conformational equilibrium towards a closed 
state, while substitution at position 528 alters the opening rate. 
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Preface 
I have contributed to other publications during my time in the laboratory of 
Lawrence Stern which will not be described within my thesis. 
In Yin et al. 2015[1], I performed experiments showing that HLA-DM has the 
same activity to catalyze peptide exchange from either monomeric or 
dimeric/aggregated HLA-DR1. This paper concluded that HLA-DM mediates 
peptide exchange on class II MHC by interacting with unbound MHC, 
MHC:peptide complex, and inactivated MHC and forming an alternate kinetic 
pathway to peptide association with MHC. 
In Stammogianos et al 2017[2], I helped plan and perform mutation of 
transient salt bridges within ERAP1, expressed these proteins, and then 
characterized these proteins via SAXS. This paper showed that disruption of 
these salt bridges, and by association other transient interdomain electrostatic 
interactions, alters ERAP1 activity, supporting a model that the closed 
conformation of ERAP1 is required for activity. The SAXS data in this paper that I 
collected is the first solution-state determination of ERAP1 conformation, which is 
open in solution. 
In Birtley et al. (under review), I performed SAXS experiments on WT OPCML 
and a clinically-relevant mutant P95R. This showed that the dimeric OPCML 
structure determined by X-ray crystallography is also present in solution, and that 
no structural deformation occurs when the mutation is present. This paper overall 
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described several structural mechanisms resulting in loss of function of OPCML, 
an endogenous tumor suppressor. 
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CHAPTER I 
Introduction 
Overview of the immune system 
As long as there has been life, it is likely there have also been pathogens[3]. 
Agents of disease (termed ‘pathogens’) subsist in an evolutionary niche infecting 
other organisms (termed ‘hosts’) and diverting resources to propagate the 
pathogen, often to the detriment of the host. In response, hosts were selected to 
have defensive systems that can prevent or reduce damage from pathogen 
interactions. In multicellular organisms, these host defenses are referred to as 
immune systems. They consist of multiple mechanisms to sense and respond to 
pathogens, since pathogens also have selective pressure to circumvent these 
defenses and have developed numerous strategies to do so[4]. 
In humans, and indeed in most vertebrates, the immune system utilizes cells 
and proteins to recognize the presence (and necessarily, the absence) of 
pathogen infection, and then to direct an immune response against this infection. 
This immune response often causes damage to infected tissues. Once the 
infection is cleared, the immune system also plays a role in recovering damaged 
tissue to homeostasis[5]. 
Pathogen detection requires sensing molecules that do not normally exist 
within the host. Some molecules such as double-stranded RNA (dsRNA) are 
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sensed by interaction with proteins that bind dsRNA without recognition of the 
oligonucleotide sequence. These broad molecular indicators of pathogen 
infection are referred to as pathogen-associated molecular patterns (PAMPs)[6]. 
Because any source of this signal is an unambiguous marker of pathogen 
activity, the immune system that targets PAMPs is termed the innate immune 
system, and immune responses against these molecules may be mounted 
immediately upon detection[7]. 
Immune systems also recognize more subtle markers of infection. The 
presence of pathogen-derived proteins (or other non-self proteins) may be 
distinguished by detecting their primary sequence and their three-dimensional 
structure. However, the host immune system is not capable of recognizing every 
undesired protein ab initio; the only reference point available initially is the 
ensemble of host proteins which should be tolerated. Once infection is mounted, 
immune cells are mobilized to search for unique identifiers of pathogen (termed 
antigens), and these are used to then develop a more specific response such as 
antibody production and/or proliferation of immune effector cells. This slower, 
more focused system is called the adaptive immune system[8]. 
 
Cell-mediated adaptive immune system 
One subsystem is referred to as the cell-mediated adaptive immune system. 
Specialized cells known as T cells express a highly variable, essentially unique 
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sensor membrane protein called the T cell receptor (TCR). This protein consists 
of a dimer of immunoglobulin-fold proteins which are generated when their genes 
each undergo a DNA splicing event. The spliced region contains some number of 
randomized nucleotides, which increases the variability of the coding sequence. 
In the translated protein, this spliced region forms a loop known as CDR3 (CDR1 
and CDR2 are within the genome-encoded regions). The CDR loops are the 
primary contacts when the TCR recognizes an antigen[9]. 
For T cells, this antigenic molecule is a peptide bound into a groove on a 
major histocompatibility complex (MHC) protein. There are two classes of MHC, I 
and II. Canonically, T cells that recognize MHC-I express a coreceptor CD8, and 
T cells recognizing MHC-II express CD4[4] (although there are exceptions to this 
trend[10-12]). Each MHC protein has a preferred peptide sequence based on the 
chemical properties of the binding pockets that anchor the peptide at particular 
positions. Class I MHC proteins additionally have a peptide length preference of 
8-11 amino acids. These two pathways (class I or II) each have distinct cellular 
processes dedicated to generating and stably binding these peptides to MHC 
proteins. The steps involved in the generation of these peptides is called antigen 
processing[4]. 
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Figure 1.1  
Overview of canonical class I MHC antigen processing pathway 
A protein is translated by the ribosome and carry out some function within the 
cell. This protein is subsequently degraded by the proteasome into peptide 
fragments. (colored ovals) Many of these are degraded by proteases within the 
cytosol. Some fraction survive this process, and a subset of these are 
transported into the ER by TAP. Some peptides may bind class I MHC (MHC-I) 
without further processing. (orange oval) Others are too long (blue+red oval), but 
aminopeptidase activity within the ER by ERAP1 and ERAP2 degrades the N-
terminal extension (red) leaving a peptide that is the right length to bind MHC-I. 
(blue oval) MHC-I then traffics to the cell surface for T cell surveillance. 
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Class I antigen processing 
Within adaptive immunity, antigen processing creates a crucial bottleneck. In 
this process, protein antigens are digested into peptides, some of which have 
appropriate sequence and length to bind the particular MHC alleles present in a 
given organism. These bound peptides are then presented to T cells. Changes in 
processing can create novel peptides that may elicit T cell response. The 
pathway to convert intact proteins into peptides capable of binding MHC-I 
molecules involves a group of cellular components. Here I will describe the 
players within the canonical pathway that produce MHC-I peptides from protein 
antigens. 
 
Proteasome 
Many cellular proteins are degraded by the proteasome. This multiunit 
molecular machine has an internal cavity into which proteins for degradation are 
threaded. This cavity proteolytically digests the target protein into peptide 
fragments 3 to 24 amino acids long, with a distribution strongly favoring smaller 
fragments(median 5-6 amino acids)[13]. While few of these fragments are of 
ideal length to bind MHC-I directly[13], this proteasomal activity is required for the 
majority of MHC-I-presented peptides[14]. Proteasome activity is known to 
change upon signaling from interferon-γ, a pro-inflammatory cytokine. Interferon-
γ signaling transcriptionally activates expression of alternate proteasomal 
 19 
 
subunits via NF-κB signal transduction[15]. The proteasome complex containing 
these subunits has been termed the ‘immunoproteasome’, and it produces 
peptide fragments with C-termini skewed towards basic or hydrophobic amino 
acids[16]. This is thought to improve the peptide pool for antigen processing by 
more closely matching peptide-binding motifs exhibited by MHC-I[15]. Another 
component activated by interferon-γ signaling is PA28, which binds to the 
proteasome[17, 18]. This PA28-proteasome complex further alters the efficiency 
of peptide hydrolysis[17, 19]. It appears that altering the pool of proteasome-
derived peptides provides some benefit in immune response[20-22], possibly by 
retaining peptide epitopes that would normally be degraded or by tailoring 
peptides to match preferred MHC-I sequence motifs[23]. 
 
Cytosolic peptidases 
In addition to the proteasome, there are cytosolic proteases that subsequently 
degrade peptides. Products of this degradation feed into metabolic pathways as 
free amino acids, and are recycled into protein synthesis pathways or are utilized 
for energy production[24]. Tripeptidyl-peptidase II (TPPII) is a serine protease 
that produces tripeptide fragments from longer peptides[25]. The role of TPPII in 
antigen processing is considered minor[26-28]. Thimet oligopeptidase is a zinc 
endopeptidase that digests peptides into smaller peptide fragments 6-9 amino 
acids in length[29], and generates some MHC-I peptides in conjunction with 
another zinc metalloprotease, nardilysin[30]. 
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Leucine aminopeptidase or cytosol aminopeptidase is an M17 family zinc 
aminopeptidase[31] that is dispensable for normal MHC-I antigen processing in 
vivo[32]. The cysteine protease bleomycin hydrolase is similarly unnecessary for 
antigen processing[33]. However, mice lacking both leucine aminopeptidase and 
bleomycin hydrolase respond more strongly to a specific viral peptide, indicating 
that these two enzymes have overlapping functions in degrading certain 
antigenic peptides[33]. Puromycin-sensitive aminopeptidase is an M1 zinc 
aminopeptidase that may destroy some MHC-binding peptides but is not 
necessary for normal immune function[34]. 
 
Transporter associated with Antigen Presentation 
Peptides generated in the cytosol must be delivered to the endoplasmic 
reticulum (ER), where empty class I MHC proteins are stabilized by specialized 
chaperone molecules in a complex known as the peptide loading complex (PLC). 
The transporter associated with antigen processing (TAP) is an ABC transporter 
protein that associates as part of the PLC[35]. TAP binds peptides 9 to 16 amino 
acids in length with equivalent affinity, with decreasing affinity for shorter or 
longer peptides[36]. TAP also is unable to transport peptides with proline at the 
second position, which is a preferred anchor residue for some MHC-I[37]. It is 
clear that transport across the ER membrane is a limiting step in the process, as 
experiments using TAP KO cells result in almost complete loss of surface MHC 
bound to peptides[38]. 
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The PLC has been structurally characterized bound by two empty MHC 
molecules[35]. The peptide-binding regions of these MHC proteins are far from 
the peptide egress pocket of TAP, and transported peptides must pass through a 
‘ventral window’ space to bind MHC. There does not appear to be a mechanism 
to spatially sequester peptides in proximity with MHC in order to promote 
association. This means that translocated peptides may interact with other 
molecules present in the ER, among which are peptidases. 
 
ER-resident peptidases 
Peptidases are present in the ER, although there are many fewer versions 
than there are cytosolic peptidases. Angiotensin-converting enzyme is a zinc 
carboxypeptidase that, in addition to its role in blood pressure regulation, 
processes peptides for both MHC-I and MHC-II pathways[39, 40]. Another 
source of MHC-binding peptides is signal peptides, which are endogenous N-
terminal tags that signal the protein translation system to express a newly-
synthesized protein into the ER[41]. Signal peptides are often cleaved from 
nascent polypeptides during ER translocation by the action of the signal 
peptidase[41]. Some MHC-I, such as HLA-E, present signal peptides of host 
proteins for immune surveillance[42]. 
 ER aminopeptidase 1 (ERAP1), the subject of this work, is a zinc 
aminopeptidase that is a major component of antigen processing[43]. In this 
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capacity, ERAP1 has a notable substrate length-dependent activity, where 
peptides longer than 8 amino acids are cleaved preferentially and with higher 
activity than shorter peptides[44, 45]. ERAP1 also favors substrates with 
hydrophobic aminoterminal residues, and has complex pattern of substrate 
sequence preferences at particular positions along the peptide sequence[46]. 
The structurally and functionally related protein ER aminopeptidase 2 (ERAP2) 
also preferentially cleaves long peptides, but the substrate sequence specificity 
of ERAP2 favors basic aminoterminal residues[47]. ERAP1 and ERAP2 appear 
to act in conjunction to process peptides to a length amenable to MHC-I binding. 
 
Discovery of ERAP1 
Initial identification of ERAP1 from a human adipocyte cDNA library described 
it as an M1 leucine aminopeptidase (designated adipocyte-derived leucine 
aminopeptidase, A-LAP) related by sequence and genomic locus proximity to 
placental leucine aminopeptidase (PLAP)[48] (otherwise designated insulin-
regulated aminopeptidase, IRAP or leucyl-cysteinyl aminopeptidase, LNPEP). In 
vitro hydrolysis assays using purified components showed that ERAP1(A-LAP) 
could digest the vasopressure-regulating peptide hormones angiotensin II and 
kallidin as well as several neuropeptides[49], though the physiological relevance 
of this activity was not described. 
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A second group characterized ERAP1 as a M1 aminopeptidase found in rat 
cells with the distinguishing feature that it was not inhibited by puromycin, and 
was termed puromycin-insensitive leucyl-specific aminopeptidase, PILS-AP[50]. 
This group also noted a strong enzymatic substrate preference for leucine and 
methionine at substrate aminotermini[50], although their data showing low activity 
for substrates with aromatic aminotermini is not consistent with later 
characterization of ERAP1.  
Up to this point, enzymatic behavior and sequence homology had been 
established, but the physiological role of this aminopeptidase was not defined. In 
close succession, two groups independently identified it as a component of MHC-
I antigen processing[51, 52]. This protein localized to the ER lumen, and as such 
was designated ER aminopeptidase 1 or ERAP1, which has become the 
predominant nomenclature (the term ER aminopeptidase associated with antigen 
processing, ERAAP, is also used but generally applies only to mice, as Rodentia 
lack the ERAP2 gene present in other vertebrates). 
ERAP1 has also been described as an effector of cytokine receptor shedding 
(with the acronym ‘aminopeptidase regulator of TNFR1 shedding’ ARTS)[53-56], 
but the significance of this finding is unclear as other proteases have been 
reported as sufficient to fulfill this role[57, 58]. ERAP1 is also reported to 
participate in vasopressure regulation[59] and in macrophage activation[60-62]. 
These roles will not be described in further detail, but any physiological role 
involving ERAP1 catalysis may be affected by the results presented in this work. 
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ERAP1 substrate length preference 
An early observation of ERAP1 activity was the relationship with ERAP1 
aminoterminal activity and the polypeptide substrate length. York et al. reported 
that N-terminal extensions of known MHC-I peptide ligands were digested more 
efficiently by ERAP1 than the unextended MHC-I-binding peptide[44]. This was 
more thoroughly examined by measuring the hydrolysis of chemically 
synthesized peptide substrates by purified ERAP1 in vitro, which showed high 
hydrolysis activity for peptides between 8 and 25 amino acids in length, but 
greatly decreased hydrolysis for shorter substrates[63]. This minimum substrate 
length-dependent behavior was unusual compared to other peptidases; however, 
this behavior was noted to resemble that of MHC-I, which exhibits a minimum 
peptide length preference of 8 amino acids[63]. This discovery yielded the 
‘molecular ruler’ model of ERAP1 activity, where the substrate peptide C-
terminus binds an activating site on ERAP1 and increases the hydrolytic activity 
by some unknown mechanism. Substrates less than 8 amino acids long would be 
unable to simultaneously occupy the aminopeptidase active site with their N-
terminus and bind the activating site simply due to the physical distance between 
these sites, which would be enforced by the structure of ERAP1[63]. 
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M1 family protein structure 
By sequence homology and structure, ERAP1 is an M1 family zinc 
aminopeptidase. These enzymes share an architecture consisting of three 
domains with a fourth domain present in some family members. The domains are 
classified numerically from N- to C-terminus. 
Domain I is predominantly composed of β-sheets. It is located in close contact 
with domain II, which holds the active site of the enzyme. Domain II is a 
thermolysin-like fold, resembling the endopeptidase of the same name from 
Bacillus thermoproteolyticus. The active site coordinates a single zinc ion which 
interacts directly with the substrate peptide. The thermolysin-like fold has two 
conserved sequence motifs, HEXXH(X18)E and GXMEN, which form much of the 
active site and the zinc-binding site. While it shares similarity with an 
endopeptidase, domain I enforces aminopeptidase activity by blocking the 
substrate binding site beyond the P1 pocket and contributing to an acidic cluster 
that binds the substrate peptide N-terminus[45, 64]. 
Domain III is another β-sheet domain that is only present in certain M1 
aminopeptidases. It appears to serve a structural role, although this has not been 
studied extensively. Domain IV is an α-helical domain which in most M1 
aminopeptidase crystal structures encloses the active site in a chamber separate 
from the bulk solvent. For aminopeptidases lacking domain III, domain IV 
consists of 9-10 helices[65], while for those containing domain III, domain IV 
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contains 16-17 helices[45, 66]; more helices allow domain IV to encompass a 
larger volume in the active site-adjacent cavity[64]. 
 
M1 family conformation  
ERAP1 was the first M1 family aminopeptidase to be crystallized in two 
separate conformations[64]. Previously, most M1 aminopeptidases were 
crystallized in the closed conformation, with the active site and bound ligands 
sequestered from solvent. This state implied that an opening step is required to 
allow substrate binding to the active site and product dissociation from it. One 
family member, Tricorn-interacting factor F3 (TIFF3) from Thermoplasma 
acidophilum, was crystallized in an open state[67]. In this state, the conserved 
domain IV is hinged away from the other domains, exposing the active site. One 
notable change in the active site is the position of tyrosine 351. In this open 
structure, the tyrosine is not oriented toward the active site[67]. Structures of 
other M1 family members such as E. coli aminopeptidase N (ePepN) found the 
corresponding tyrosine (amino acid 381 in ePepN) oriented with the sidechain 
phenol in proximity to the catalytic zinc and contacting the bound substrate 
analog inhibitor bestatin. For S. cerevisiae leukotriene A4 hydrolase, another M1 
family member, mutation of the catalytic tyrosine (amino acid 429) to 
phenylalanine caused a loss of aminopeptidase activity, indicating the 
importance of this phenol group to catalysis[68]. The sum of these prior 
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structures suggested that motion of the catalytic tyrosine might coincide with the 
large-scale conformational change of domain IV. 
ERAP1 open and closed crystal structures confirmed that this tyrosine (amino 
acid 438 in ERAP1) did adopt a conformation-dependent position as observed for 
M1 family structures[64]. In contrast to this, open and closed structures of the 
mammalian aminopeptidase N (also designated CD13) showed the catalytic 
tyrosine (amino acid 472 in porcine aminopeptidase N) remained in the 
catalytically active position despite the conformation of domain IV[69-71]. This 
proves that active site perturbation connected to conformational change is not 
obligatory for M1 family aminopeptidases. Open and closed conformations of 
IRAP show an intermediate motion of catalytic tyrosine 549[72-74]. It remains to 
be determined if ERAP1 and IRAP, two of the members of the oxytocinase 
subfamily of M1 aminopeptidases, are broadly relevant models of M1 family 
behavior of conformationally activated catalytic site geometry, or if they are the 
exception. 
 
Peptide C-terminal binding site 
The molecular ruler model of ERAP1 activity hypothesized the existence of a 
dedicated substrate peptide C-terminal binding site that activates ERAP1 
hydrolysis. Identification of this site would provide new insight into the 
mechanism of ERAP1 activation. Understanding the substrate requirements for 
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ERAP1 activity would also assist in predicting which MHC-binding peptides are 
present in cells, and might explain the behavior of certain ERAP1 disease-
associated polymorphisms (see subsequent sections for additional details). 
Crystal structures of ERAP1 fragments (containing domains III and IV only) 
serendipitously implicated a subsite within domain IV as a peptide substrate C-
terminus binding site[75, 76]. In these structures, a C-terminal tag from one unit 
cell contacts the ERAP1 domain IV of the neighboring unit cell. This site of 
contact lies in the center of the helical repeats that comprise domain IV, which 
has been previously suggested as a binding site due to its geometry, its distance 
from the active site (which is consistent with the molecular ruler model of ERAP1 
activity), and its electrostatic properties[64]. However, it remains unclear 
mechanistically how this site recognizes occupancy of a peptide C-terminus. No 
experiments are published demonstrating the importance of this site through 
mutagenesis or other functional experiments. Additionally, the substrate internal 
sequence specificity of ERAP1, which includes a preference for either 
hydrophobic or basic amino acids at the substrate C-terminus, is quite broad[46]. 
One explanation is that there may be multiple substrate C-terminal binding sites 
to accommodate the broad scope of substrates that ERAP1 hydrolyzes. As such, 
the crystallized binding site remains plausible but still inconclusive. 
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ERAP1 alters antigen processing and immune function 
The role of ERAP1 on cell-mediated immune responses has been studied in 
mouse models as well as human samples. ERAP1 knockout (KO) mice have 
altered immune responses to pathogens[43, 77-79]. Hosts respond to pathogen 
infections by targeting a specific subset of peptide epitopes, a process termed 
immunodominance. These preferred epitopes are highly reproducible for model 
organisms expressing identical MHC proteins. However, ERAP1 KO mice have 
an altered immunodominance hierarchy. This indicates that some aspect of 
peptide processing has been altered in these mice. This alteration due to ERAP1 
KO was found to impair survival in mice infected with Toxoplasma gondii[80]. No 
defect in survival was observed for the model pathogens lymphocytic 
choriomeningitis virus (LCMV) and Vaccinia virus[43, 77]. Pathogen-specific 
survival hypothetically results from differences in the importance of host CD8+ T 
cell responses in clearing the infection, which is related to the efficiency of MHC-I 
antigen processing of proteins from a given pathogen. 
Another indication of the relevance of ERAP1 to immune response is the 
observation that ERAP1 is a target of immune evasion by pathogens as well as 
in oncogenesis. The pathogen human cytomegalovirus (HCMV), which is 
prevalent in most mammalian species, expresses two microRNAs (miRNAs) to 
suppress expression of ERAP1[81, 82]. This interferes with MHC-I antigen 
presentation of viral peptides to surveilling CD8+ T cells specific to HCMV[81]. 
This pathogen strategy has selected for a host ERAP1 single nucleotide 
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polymorphism (SNP) within one miRNA binding site that escapes the pathogen-
induced decrease in expression[82]. 
It is also notable that alterations in ERAP1 expression occur in cancer. 
ERAP1 expression varies depending on the tissue progenitor of the cancer, likely 
conferring protection by disrupting tissue-specific antigen processing[83]. In two 
examples, ERAP1 activity destroys tumor-specific peptides for MHC-I 
presentation in a colon carcinoma cell line (CT26) and confers protection from 
immune response[84], but in a separate carcinoma cell line (16.113) ERAP1 
produces peptide epitopes that induce a CD8+ T cell response[85]. This 
exemplifies the highly context-specific effect of ERAP1 activity, which is altered 
depending on the available peptides and the MHC alleles present. 
Additional experimentation using syngeneic transplantation identified that the 
alteration in antigen processing is immunogenic in the absence of pathogen. 
ERAP1 KO cells transplanted into WT mice stimulate a concerted immune 
response, as does the opposite transplantation[86, 87]. This same response 
occurs when the transplanted cells are deficient in ERAP1 activity by application 
of an in vitro small molecule inhibitor L-leucinethiol rather than through genetic 
deletion[86]. A large fraction of these responding T cells react to a host peptide 
originating from the uncharacterized protein Fam49b[86]. This peptide is 
constitutively expressed but is destroyed by ERAP1 activity. This appears to be 
an endogenous system present in mice to monitor ERAP1 activity and to 
generate an immune response if ERAP1 activity is inhibited[86]. 
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These latter examples highlight a critical dichotomy present in the cell-
mediated adaptive immune system: the abundance of antigens during and after T 
cell development. 
 
T cell development 
As T cells develop, they generate their TCR as described previously. The 
inherently random nature of this event initially produces many genes that have 
negligible binding affinity for any MHC:peptide complex. These are not productive 
as antigen sensors due to their lack of binding sensitivity. Other TCR 
recombination events generate sensors that are highly reactive to host proteins 
or peptides (which normally bind MHC even in the absence of pathogen). These 
receptors are not desirable antigen sensors as they lack specificity. 
In order to filter these two categories of TCRs, T cells undergo positive 
selection (where they must exhibit baseline binding sensitivity to survive) and 
negative selection (eliminating cells with high binding affinity to host MHC:peptide 
complexes, i.e. low specificity)[88]. This, in principle, leaves a pool of T cells with 
TCRs that are not self-reactive but are tuned with affinity just below the threshold 
for cell activation. A pathogen antigen that activates these T cells may or may not 
exist, but this information is not available to incorporate into the selection process 
prior to infection. The only parameters available for filtering during development 
are the specific host MHC haplotype (MHC molecules are highly polymorphic) 
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and the specific host peptides present. If either of these components change, T 
cells selected under one set of criteria may encounter a reactive MHC:peptide. 
Additionally, the continuum of T cell reactivity against host antigens permits 
the possibility for autoimmune disease. Partially self-reactive T cells that survive 
negative selection during T cell development are generally prevented from 
activating upon recognition of a host antigen, a condition referred to as 
tolerance[89]. One model of the breakdown of tolerance states that an injury or 
inflammatory event such as a pathogen infection activates T cells somewhat 
nonspecifically and overcomes the suppression of these marginally self-reactive 
T cells[90, 91]. Once these cells begin a response against a host antigen, a 
positive feedback loop amplifies the effect. 
Among the factors that contribute to loss of tolerance, it is apparent that 
incidence of autoimmune disease correlates with certain MHC alleles and with 
certain allelic variants of proteins that perform antigen processing, including 
ERAP1. 
 
ERAP1 polymorphism rs30187 
In humans, several prevalent SNPs have been identified within ERAP1. 
Among these, rs30187 (T/C), a nonsynonymous SNP within codon 528 
(lysine/arginine respectively) has been identified as the most significant factor in 
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disease incidence and is a modulator of enzymatic activity. This SNP is common, 
with a global minor allele (T, encoding lysine) frequency of 0.4114[92]. 
 
SNP rs30187 correlates with disease 
Polymorphism rs30187 was first identified as a correlate with 
hypertension[93]. ERAP1 with arginine 528 was shown to have decreased 
hydrolytic activity compared to lysine 528, leading to the hypothesis that 
decreased capacity of Arg528 ERAP1 to degrade the hypertensive hormones 
angiotensin II and kallidin resulted in prolongation of these hypertensive signals 
and increased prevalence of hypertension in humans carrying the “arginine 528” 
ERAP1 variant[94]. 
Subsequent GWAS identified rs30187 as a correlate with ankylosing 
spondylitis (AS) incidence[95, 96]. AS is an autoimmune disorder with arthritic 
symptoms that is highly heritable and is associated closely (but not exclusively) 
with the MHC-I allele HLA-B27[97]. Within the HLA-B27-positive population, 
ERAP1 SNP rs30187 “T” (encoding lysine 528) is a dose-dependent risk factor 
for AS incidence[96]. While the disease mechanism may be complex and 
multifactorial, the correlation of a particular MHC-I along with a particular 
component of class I MHC antigen processing implicates a CD8+ T cell response 
in the disease process. SNP rs30187 “T” also correlates with psoriasis[98, 99] 
and Behçet’s disease[100] incidence.  
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SNP rs30187 effect on ERAP1 protein structure and function 
Biochemical and enzymatic analysis of recombinant ERAP1 with 
lysine/arginine substitution at position 528 revealed that the nonsynonymous 
polymorphism rs30187 significantly alters ERAP1 activity. Both variants express 
recombinantly in comparable quantities[94, 101]. Structurally, ERAP1 with either 
lysine or arginine at position 528 (in addition to other polymorphic site variants) 
have both been crystallized in the open conformation, and no notable alterations 
were observed[45, 64].  
Variation at position 528 is known to alter the enzymatic properties of ERAP1. 
Arginine 528 ERAP1 has been described in many reports as a hypoactive variant 
of ERAP1 relative to lysine 528 ERAP1[64, 94, 102]. Peptide hydrolysis 
experiments under Michaelis-Menten conditions clarified that this altered activity 
is substrate-dependent; in the most distinct case (decamer peptide substrate 
LATFPDTLTY), arginine ERAP1 has increased KM and kcat compared to lysine 
528[101]. For some peptides, substrate inhibition is also observed differentially 
for the different ERAP1 variants[101]. This indicates that the effect of position 
528 on ERAP1 catalysis cannot simply be described as increasing or decreasing 
activity. 
Proteomic analysis of MHC-bound peptides is a developing method to assess 
antigen processing and presentation. Polymorphism rs30187 has been reported 
to alter the MHC-bound peptidome, where the peptide N-terminal amino acid 
tends to be bulkier (greater molecular weight) and a weaker ERAP1 substrate 
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when lysine 528 ERAP1 is expressed relative to arginine 528[103, 104]. ERAP1 
polymorphism-dependent differences in the MHC-bound peptidome may explain 
the disease correlates of these ERAP1 polymorphisms, as a hypothetical peptide 
might display some propensity for inducing an autoimmune response, and 
processing of this peptide might be altered by ERAP1 polymorphism. 
Alternatively, the MHC-I peptidome (all peptides bound to class I MHC in a given 
cell/tissue/organism) may differ in binding stability or some other parameter in the 
presence of either polymorphic variant.  Alterations in this manner have been 
observed and may be sufficient to induce autoimmune disease[104]. 
 
ERAP1 polymorphisms are inherited as discrete alleles 
The association of ERAP1 SNPs with disease does not fully describe the 
relevant ERAP1 alleles present in the human population. Several other ERAP1 
SNPs have been identified that associate with disease[95, 96, 100]. These SNPs 
do not segregate independently from one another, but exhibit genetic heritability 
as a set of alleles[102, 105]. Classification of ERAP1 alleles and their disease 
correlation and effect on the MHC peptidome as haplotypes of alleles rather than 
separate SNPs is ongoing[102, 106-108]. 
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Small-molecule inhibitors of ERAP1 
Small-molecule inhibitors of aminopeptidases have been used as molecular 
probes, purification reagents, and therapeutic agents for several decades. One 
commonly used inhibitor is bestatin, also known as ubenimex, a dipeptide 
substrate mimic that was first discovered as a natural product of the bacteria 
Streptomyces olivoreticuli[109]. Another similar inhibitor is amastatin, which is a 
tetrapeptide mimic isolated from Streptomyces ME98-M3 strain[110]. These 
compounds are broad aminopeptidase inhibitors with ERAP1 inhibition constants 
between 10-300µM[48, 52, 94]. One interesting observation is the differential 
inhibition of ERAP1 polymorphic variants at position 528, where these 
compounds have inhibition constants three- to five-fold greater for arginine 528 
ERAP1 than lysine 528 ERAP1[94]. 
ERAP1 crystal structures were determined with bestatin bound at the active 
site in both the open and closed conformations[45, 64]. Bestatin is oriented 
similarly in these two structures, with the hydroxyl and the carbonyl oxygen 
bracketing the ERAP1 catalytic zinc. (Figure 1.2) In the closed conformation, 
phenylalanine 433 is visualized in ERAP1, and makes a π-π interaction with the 
bestatin phenyl group; this phenylalanine is not ordered in the open 
conformation[45, 64].   
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Figure 1.2  
Bestatin, a dipeptide mimic, binds the active site of ERAP1. 
(a) Structural formula of bestatin. (b) Bestatin, green, bound to ERAP1 in the 
closed conformation, cyan(PDB ID 2YD0)[64]. Hydroxyl and carbonyl oxygens 
contact catalytic zinc, gray sphere. (c) Bestatin as in (b) bound to ERAP1 in the 
open conformation, magenta(PDB ID 3MDJ)[45]. 
 
 
c b 
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Bestatin treatment has been shown to alter immune function. In vitro experiments 
using primary immune cells showed that bestatin boosted lymphocyte 
proliferation when cells were nonspecifically stimulated with molecules such as 
phytohemagglutinin (PHA) or the bacterial product lipopolysaccharide 
(LPS)[111]. Bestatin treatment in mice increases the severity of delayed 
hypersensitivity reactions[112, 113]. These reactions are a class of immune 
response mediated by T cells[4]. This immunostimulatory behavior was attributed 
to the inhibition of aminopeptidases other than ERAP1, as these experiments 
predated the discovery of ERAP1, but the inhibition of ERAP1 would alter antigen 
processing during a developing immune response and is a plausible mechanism 
to produce these results. 
Another broad aminopeptidase inhibitor is L-leucinethiol[114]. This 
mercaptoamine compound is proposed to react with active-site zinc ions present 
in zinc peptidases[115]. This compound is also likely to react with other redox-
active functional groups. Leucinethiol inhibits ERAP1 with submicromolar 
potency[52, 94]. 
Leucinethiol has been used in several experiments to test the effect of 
ERAP1 inhibition on antigen processing and immune function. As noted earlier in 
this work, leucinethiol-treated cells introduced into mice were shown to be 
immunogenic[86]. Leucinethiol treatment impaired antigen processing in cultured 
cells in a MHC allele-specific manner, indicating that MHC proteins have 
differential preferences for aminoterminally-processed peptides[116].  
 39 
 
Zinc-chelating groups such as aminobenzamide have been investigated as 
ERAP1 inhibitors[117, 118]. Some derivatives have submicromolar potency for 
ERAP1, but these compounds are also inhibitory to the related oxytocinase 
subfamily aminopeptidases ERAP2 and IRAP. As these enzymes all function 
within antigen processing, selectivity is required to parse the functional effects of 
inhibition. 
Phosphinic inhibitors such as DG013 also exhibit nanomolar potency for the 
oxytocinase subfamily of M1 aminopeptidases[119, 120]. This peptidomimetic 
scaffold binds the active site with the phosphinic group mimicking the tetragonal 
transition state of peptide bond hydrolysis. Phosphinic peptides have been 
crystallized bound to ERAP2 and IRAP to identify the determinants of substrate 
sequence recognition in these enzymes[72, 74, 119, 121]. These inhibitors have 
been utilized in some cell culture assays to inhibit aminopeptidases in antigen 
processing[119]. While some of these phosphinic compounds demonstrate 
selective inhibition for ERAP2, most have significant potency against all three 
members of the oxytocinase family. 
 
Open questions regarding ERAP1  
The enzyme ERAP1 remains the focus of scrutiny due to its physiological 
roles (especially within antigen processing) and the extremely complicated 
relationship between ERAP1 sequence variants and disease incidence. One 
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crucial aspect of ERAP1 function is the minimal substrate length preference. The 
molecular ruler model of ERAP1 proposed one model of allosteric activation by 
sufficiently long substrates, but the location of the site(s) of allosteric activation 
remains unclear, as is the mechanism in which allosteric binding relates binding 
to catalytic activation. Binding site identification would help define the amino acid 
sequence and length parameters that make a peptide a preferred ERAP1 
substrate. This understanding would improve the accuracy of antigen processing 
prediction[122]. It would also test the validity of the molecular ruler model of 
ERAP1 function and might explain the effect of SNPs on ERAP1 activity. 
The conversion of ERAP1 between states is demonstrated by two crystal 
structures, giving atomic-level detail of two states that ERAP1 may adopt, and 
computational simulation has predicted additional states that may exist, but the 
relationship of conformational change with ERAP1 catalysis remains 
hypothetical. The rates of conformational change are also of interest in order to 
dissect the enzymatic model of ERAP1 function. SNP-dependent effects on 
ERAP1 behavior have been proposed but remain untested. More broadly, the 
role of conformational change for the entire M1 aminopeptidase family is 
hypothetically relevant but has not been identified experimentally. 
One approach currently used to study ERAP1 function is measuring changes 
in immune function or in antigen processing upon ERAP1 expression or 
inhibition. Much of this work has used genetic modulation such as gene 
knockouts[79], or alterations of protein expression by transfection[102] or RNA 
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interference[123]. While specific, these approaches do not permit perturbation of 
ERAP1 activity in a time-dependent manner. Quantifying the kinetics of ERAP1 
antigen processing would inform the overall rate at which immune responses 
form. Development of truly selective small molecule inhibitors against ERAP1, 
ERAP2, or IRAP would allow deeper investigation of their respective roles in 
homeostasis and disease. Additionally, the use of small-molecule inhibitors to 
specifically alter ERAP1 activity provides a novel approach to modulate immune 
responses, both as an experimental tool to perturb in vivo models of disease and 
potentially as a clinically relevant therapeutic approach. 
In this thesis I present the identification and characterization of ERAP1-
specific small molecule inhibitors. Additionally, I report the observation of ERAP1 
conformational change upon binding substrates and inhibitors, and identify that 
substitution of lysine or arginine at position 528 alters rates of conformational 
change. 
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CHAPTER II 
Discovery of specific inhibitors of endoplasmic reticulum 
aminopeptidase 1 
This chapter corresponds to a manuscript in preparation: 
Maben Z, Golden J, Rane D, An WF, Metkar S, Hickey M, Bender S, Schilling R, 
Arya R, Nguyen TT, Evnouchidou I, Stratikos E, Stern LJ. “Discovery of specific 
inhibitors of endoplasmic reticulum aminopeptidase 1.” 
 
Author contributions 
I expressed and purified proteins for assays, optimized scalable assays for high-
throughput screening, and performed confirmatory activity assays. I also 
performed peptide hydrolysis assays, in silico docking, and cellular inhibition 
experiments, analyzed and interpreted data, and wrote this manuscript with input 
from coauthors. 
 
ABSTRACT 
ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays 
an important role in the immune system by trimming peptides for loading onto 
major histocompatibility complex (MHC) proteins. Here we report discovery of the 
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first inhibitors selective for ERAP1 over its paralogs ERAP2 and IRAP. 
Compounds 1 (1-(2,5-difluorophenyl)sulfonyl-2-[2-(1H-indol-3-yl)ethyl]guanidine) 
and 2 (1-[1-(4-acetylpiperazine-1-carbonyl)cyclohexyl]-3-(4-methylphenyl)urea) 
are inhibitors of ERAP1’s leucine aminopeptidase activity, and compound 3 (4-
methoxy-3-[[2-piperidin-1-yl-5-(trifluoromethyl)phenyl]sulfamoyl]benzoic acid) is 
an allosteric activator of this activity. All three compounds inhibit ERAP1’s ability 
to hydrolyze a 10mer peptide substrate, and compounds 2 and 3 inhibit antigen 
presentation in a cellular assay. Compound 3 displays even higher potency for 
an ERAP1 variant that correlates with autoimmune disease incidence. These 
inhibitors provide mechanistic insight into the determinants of specificity for the 
three related enzymes ERAP1, ERAP2 and IRAP, and offer a new therapeutic 
approach of specifically inhibiting ERAP1 activity in vivo. 
 
INTRODUCTION 
Endoplasmic reticulum aminopeptidase 1 (ERAP1, also known as ARTS1, 
ALAP, ERAAP, or PILS-AP) is a 107kDa M1 family zinc aminopeptidase (EC 
3.4.11.-)[48] ubiquitously expressed in somatic cells[51]. ERAP1 trims peptides in 
the endoplasmic reticulum prior to their presentation on class I major 
histocompatibility complex (MHC) proteins. ERAP1 has length specificity unique 
among aminopeptidases, efficiently trimming peptides longer than ~8 residues 
but sparing shorter peptides[45], matching the length preferences of MHC[63]. A 
model for ERAP1’s length dependence has been proposed whereby long but not 
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short peptide substrates are able to access a regulatory site to activate their own 
hydrolysis[45, 75]. ERAP1 exhibits broad but defined substrate sequence 
specificity with preference for bulky hydrophobic P1 and either bulky hydrophobic 
or basic PΩ’[46, 124]. 
ERAP1 processing can result in generation or degradation of peptides able to 
bind MHC, and as a result ERAP1 impacts a large fraction of the overall MHC-
bound peptide repertoire[43, 87]. After loading, MHC traffics to the cell surface 
where are they are assessed by circulating T lymphocytes as part of immune 
surveillance of bodily tissues for infection or malignancy. Polymorphisms in 
ERAP1 are associated with increased susceptibility to T-cell mediated 
autoimmune diseases[125] and cancer[126, 127]. ERAP1 also has been 
implicated in regulation of blood pressure[59, 93] due to its ability to hydrolyze 
angiotensin II[49]. Alterations in vasopressure regulation in knockout mice 
lacking the gene thiol reductase ERp44 implicated this physiological effect stems 
from unregulated secretion of ERAP1, which is retained in the ER through 
intermolecular interaction with ERp44[59]. 
In humans the erap1 gene is found together with paralogs ERAP2 and IRAP 
in a gene cluster on chromosome 15 and the corresponding proteins form the 
oxytocinase subfamily of M1 aminopeptidases. Endoplasmic reticulum 
aminopeptidase 2 (ERAP2, also knows as L-RAP, EC 3.4.11.-) plays a role in 
antigen processing similar to ERAP1 but with a different substrate peptide 
sequence preference[124]. Insulin-regulated aminopeptidase (IRAP, EC 
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3.4.11.3), also known as placental leucine aminopeptidase (PLAP), oxytocinase, 
and leucyl-cystinyl aminopeptidase, plays an analogous function but in 
endosomes rather than the endoplasmic reticulum, processing peptides in the 
class I MHC cross-presentation pathway[128, 129]. IRAP also performs 
metabolic, neurological and endocrine functions[130-132]. Understanding the 
specific contributions of the different oxytocinase subfamily aminopeptidases is of 
interest to both basic and applied research. 
ERAP1, ERAP2 and IRAP all have been implicated in processing antigens for 
presentation by MHC proteins, and several approaches have been used 
delineate each of their specific effects. Inhibitors with high ERAP1 specificity 
allow ERAP1 function to be probed in a manner distinct from genetic 
deletion[133], expression modulation via RNAi knockdown[44], and from less 
specific inhibitors[116]. While highly specific, genetic mutation or deletion does 
not give information on the kinetic role ERAP1 plays in antigen processing. RNAi 
knockdown shares this drawback to some degree, and additionally may be 
complicated by incomplete knockdown or off-target effects. 
One approach that could be used to distinguish the roles of these 
aminopeptidases is treatment with small molecule inhibitors. However, highly 
specific inhibitors of ERAP1 have not been identified despite many efforts. 
Bestatin[109] and amastatin[110] have poor potency for ERAP1[48] and 
promiscuous inhibition of other aminopeptidases.[134, 135] Leucinethiol is a 
relatively potent ERAP1 inhibitor[114], but also inhibits many other 
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peptidases[136]. Other inhibitors act by interaction with the catalytic zinc and 
surrounding residues, which are well conserved among this enzyme family[117, 
137]. Small molecule inhibitors of other M1 aminopeptidases have been 
identified, notably for PfA-M1, an enzyme expressed by P. falciparum during 
malaria infection[138]. Several potent peptide-based inhibitors of M1 
aminopeptidases as well as other zinc proteases have been developed rationally 
using a phosphinate group as a substrate transition state analog[139-142]. 
However, as M1 zinc aminopeptidases reaction mechanisms and active site 
geometry are highly conserved, inhibitors in this class exhibit significant potency 
for multiple M1 aminopeptidases[120]. These compounds also are limited in their 
in vivo utility due to their similarity to peptides, which are hampered by 
proteolysis and cell membrane impermeability. As ERAP1, ERAP2 and IRAP 
each perform different but related immune functions, the effect of broad inhibition 
may have dire consequences. The clinical implications of either specific or broad 
inhibition are still unknown but may have a significant impact on treating human 
disease[143, 144]. 
In this study we developed a screening strategy to identify small-molecule 
compounds selective for ERAP1 over other oxytocinase family aminopeptidases 
ERAP2 and IRAP. Compounds with three different chemical frameworks were 
identified for optimization and testing using physiologically relevant substrate 
processing assays. Two of these compounds specifically inhibit ERAP1’s cellular 
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antigen processing activity. Compounds 1 and 2 target ERAP1’s active site, 
whereas compound 3 targets an allosteric regulatory site. 
 
RESULTS 
Assay development 
ERAP1 enzymatic activity is conveniently assayed using the fluorogenic 
substrate leucine-7-amido-4-methylcoumarin (Leu-AMC), which is analogous to a 
dipeptide substrate[48]. Since this is shorter than preferred substrates, ERAP1 
hydrolysis activity of Leu-AMC is substantially lower than for more physiologically 
relevant peptides of 8 more residues[45] but can be measured easily by 
fluorescence in microtiter format HTS assays. A preliminary screen using the 
LOPAC 1280 library of pharmaceutically relevant compounds identified several 
redox-active compounds as potent inhibitors of ERAP1, likely due to reaction with 
of ERAP1’s disulfide bonds or free cysteine residues. Additionally, several 
compounds were identified that activated ERAP1’s Leu-AMC hydrolysis activity, 
an activity previously observed for short peptide substrates and attributed to 
binding a hypothesized regulatory site within the overall substrate binding 
region[45, 75]. 
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Inhibitor screen 
 In order to identify novel ERAP1-specific inhibitors, we designed and 
implemented a high-throughput screen of the NIH’s Molecular Libraries Probe 
Production Centers Network library at the Broad Institute’s Probe Development 
Center. (Figure 2.1) We screened for compounds that inhibit ERAP1 Leu-AMC 
hydrolysis activity at a single concentration (10.7µM). Compounds that 
decreased ERAP1 Leu-AMC hydrolysis activity by 30% were filtered by 
cheminformatic analysis and by further assays for dose-dependent efficacy. 
Compounds showing dose-dependent inhibition were then counterscreened for 
inhibition ERAP2 or IRAP activity. This reduced the pool of candidate compounds 
to two Leu-AMC inhibitors. 
We identified two compounds as specific inhibitors of ERAP1-catalyzed 
hydrolysis of Leu-AMC. (Figure 2.2b, bottom) These compounds (1 and 2) have 
distinct chemical scaffolds, where 1 is a phenylsulfonylguanidine and 2 is a 
piperazinylphenylurea. We tested compounds 1 and 2 in a subsequent 
confirmatory Leu-AMC hydrolysis assay and they exhibit ERAP1 Leu-AMC IC50 
of 9.2µM and 5.7µM respectively. They are also more than 100-fold more specific 
for ERAP1 than ERAP2 (Figure 2.2b, bottom) and IRAP (Figure 2.2c, bottom) , 
and in some cases no activity for ERAP2 and IRAP was detected. 
We tested the effect of these inhibitors on ERAP1-catalyzed hydrolysis of a 
decamer peptide WRCYEKMALK, which is a more physiologically relevant 
ERAP1 substrate. (Figure 2.3) ERAP1 hydrolyzes the N-terminal tryptophan and   
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Figure 2.1 
Screening pathway identifies three ERAP1-specific compounds. 
The MLPCN library was screened for alteration of ERAP1 activity. Inhibitors and 
activators were further screened to remove known problematic scaffolds and 
moieties as well as peptidomimetic compounds. Remaining compounds were 
then tested for potency with a cutoff EC50 of 10µM. We observed several 
candidate compounds contained coumarinyl groups and removed these out of 
concern for false positives. We then counterscreened the compound pools for 
activity on ERAP2 and IRAP.  
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Figure 2.2 
Hit compounds are highly specific for ERAP1. 
Enzyme activity was measured using dipeptide substrate analog X-7-amido-4-
methylcoumarin (X-AMC), where the aminoterminal residue X is leucine (ERAP1, 
IRAP) or arginine (ERAP2), corresponding to the substrate preference of each 
enzyme[128]. Hydrolysis was measured over a range of compound 
concentrations for (a) ERAP1, (b) ERAP2, or (c) IRAP. Activity was normalized to 
the activity of the enzyme in the presence of DMSO. Shown are representative 
data (mean ± SD, N=3) from one of two experiments. Data points were fit using a 
sigmoidal curve with the top or bottom value for inhibitor or activator curves, 
respectively, constrained to 100%.  
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Figure 2.3 
Hit compounds inhibit ERAP1-catalyzed peptide hydrolysis. 
(a) ERAP1 catalyzes hydrolysis of the N-terminal tryptophan from the peptide 
WRCYEKMALK. MALDI spectrum after 30-minute incubation with ERAP1. 
Calculated masses are shown at top, and observed peak m/z are displayed on 
the graph. (b) Hit compounds inhibit ERAP1-catalyzed peptide hydrolysis. 
Representative data (n=2) normalized to DMSO control condition shows 
inhibition of peptide hydrolysis. Mean and SD IC50 values derived from eight 
individual dilution series are reported.  
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Figure 2.4 
Compound 2 structure-activity relationship analysis. 
Representative peptide hydrolysis data shown (n=2) demonstrates most 
alterations at each position decreases potency, except for one R3 variant, 10. 
Compound 2 (yellow) data is shown in each graph for comparison. Variants 
replace the circled group with the moiety depicted in the legends. 
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releases the nonamer product peptide RCYEKMALK. This assay quantifies 
product peptide production by LC-MS, and so does not require a non-natural 
probe for detection. (Figure 2.3a) All compounds inhibited peptide hydrolysis in a 
dose-dependent manner. (Figure 2.3b)  We observed that peptide hydrolysis IC50 
values closely matched the respective IC50 values for Leu-AMC hydrolysis.  
Inhibitor structure-activity relationship analysis 
After determining these compounds inhibit ERAP1-catalyzed hydrolysis of this 
peptide substrate in vitro, we created derivatives to map the interaction of 
chemical moieties with ERAP1. We selected compound 2 due to its greater ease 
of synthesis. (Figure 2.4) Variation at most sites resulted in a loss of potency. 
One variant, wherein a 4-methylphenyl group at the R3 position is replaced with a 
4-chlorylphenyl group, showed a two-fold IC50 reduction in both Leu-AMC and 
peptide hydrolysis assays. 
 
Activator screen 
 Based on results from the LOPAC preliminary screen and previous work on 
allosteric activation of ERAP1[45, 75], we also screened for compounds from the 
initial screen that increased Leu-AMC activity. We initially selected compounds 
that increased Leu-AMC hydrolysis by 40% (3 standard deviations) over control 
for further characterization. (Figure 2.1, on right) After dose-dependent   
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Figure 2.5 
Compound 3 structure-activity relationship analysis. 
Representative peptide hydrolysis data shown (n=2) demonstrates most 
alterations at each position decreases potency, except for one R4 variant, 67. 
Compound 3 (blue) data is shown in each graph for comparison. Variants replace 
the circled group with the moiety depicted in the legends. 
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confirmation, cheminformatic analysis, and selectivity counterscreening as for 
inhibitors previously, we identified one ERAP1-specific compound, 3.  
Compound 3 activates ERAP1 hydrolysis of Leu-AMC (Figure 2.2a, top), with 
an AC50 of 3.7µM and a maximum activity of 4.1-fold over control. This 
compound inhibits ERAP2 with an IC50 greater than 200µM, and has no 
detectable effect on IRAP activity. (Figure 2.2b,c; top) As previously observed for 
short peptides[45], ompound 3 activates Leu-AMC hydrolysis but inhibits peptide 
hydrolysis. (Figure 2.3) 
 
Activator structure-activity relationship analysis 
Derivatization of compound 3 produced many compounds with decreased 
potency. (Figure 2.5) One variant at position R4 (substituting a 1-methyl-
piperazinyl group for a piperidinyl group) had equivalent activity to the parental 
compound. None of the modifications tested resulted in significant improvement 
in potency. We suggest that this compound might make numerous contacts with 
ERAP1 across its entire structure, with contacts at many sites required for 
activity. 
 
Molecular docking identifies compound binding sites 
 The identification of binding sites for these three hit compounds may help in 
the design of more potent compounds. In order to determine binding sites, we 
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docked compounds in silico to a structure of ERAP1 based on an existing crystal 
structure[64]. (Figure 2.6) Compounds 1 and 2 are predicted to bind at the active 
site, making interactions with the catalytic zinc and some catalytic residues in 
domain II. Both compounds also interact with residues outside the canonical M1 
family active site, where 1 interacts closely with domain IV, and 2 makes contacts 
with portions of domain II distal from the active site. Compound 3 docked in a 
pocket formed at the interface between domains II and IV in the closed ERAP1 
structure, far from the active site. 
 
Inhibition of intracellular peptide processing 
Among the potential uses of specific ERAP1 inhibitors is the application of 
these compounds in vivo for therapeutic treatment. To evaluate potential utility in 
this application we tested all hit compounds in a cellular assay modified from a 
previously described method[44]. We measured the amount of SIINFEKL (a 
model class I peptide) bound to MHC H-2 Kb at the cell surface using an 
antibody for this specific complex. (Figure 2.7a) To quantify peptide 
aminoterminal processing, we compared the amount of MHC:SIINFEKL complex 
on cells expressing an N-extended SIINFEKL peptide to a control condition 
where the SIINFEKL peptide is generated without aminopeptidase activity.   
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Figure 2.6 
In silico docking identifies binding sites for hit compounds. 
(a) Hit compounds (shown as spheres) docked to closed ERAP1 docking model 
(shown as cartoon, colored by domain). (b) Compound binding sites. ERAP1 
surface is colored by domain as in (a). Compounds are shown as sticks. 
 
  
Figure 6. in silico docking identifies binding sites for hit compounds.  (a) Compounds (shown as spacefill) docked 
to closed ERAP1 docking model (shown as cartoon, colored by domain). (b) Compound binding sites.  ERAP1 
surface is colored by main as in (a).  Compoun s are shown as sticks. 
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Figure 2.7 
Two hit compounds inhibit ERAP1 activity in cells. 
(a) Cartoon depicting experimental design. Cells express SIINFEKL peptide ( ) 
with N-terminal extension ( ).  ERAP1 ( ) must trim the peptide to allow binding 
to MHC protein ( ). ERAP1 activity is quantified by measuring surface 
MHC:SIINFEKL complex with a specific antibody. (b) ERAP1 inhibition using the 
nonspecific zinc peptidase inhibitor leucinethiol (Leu-SH). Samples are gated on 
GFP+ singlets prior to median fluorescence intensity (MFI) quantification of 
surface MFI:SIINFEKL complex. (c) Compounds 2 and 3 are active in cell 
processing assay at 50µM.  MFI is normalized to DMSO sample and to a control 
well with cells expressing ubiquitin-SIINFEKL which is processed independent of 
ERAP1 activity. Shown are representative data (single well) of two experiments. 
(d) Compounds 2 and 3 are active in cell processing assay in a dose-dependent 
manner. Data was processed as in (c). Data points from three separate 
experiments are plotted together with one global sigmoidal curve calculated for 
each compound.  
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Treatment of cells with the nonspecific inhibitor leucinethiol decreases 
staining intensity only in cells expressing the N-extended peptide. (Figure 2.7b) 
Compounds 2 and 3 inhibit peptide processing in this cellular assay, while 1 was 
inactive at 50µM. (Figure 2.7c) The inhibition is dose-dependent, and compound 
3 exhibits the highest potency with IC50 of 1.04µM. (Figure 2.7d) 
 
Differential efficacy of compound 3 on ERAP1 alleles 
ERAP1 has several alleles present at high frequency in the human 
population, some of which correlate with susceptibility or resistance to 
autoimmune diseases such as ankylosing spondylitis[108]. We tested the effect 
of compound 3 on different ERAP1 alleles at high substrate concentration, 
necessitating the use of the dipeptide substrate leucine-p-nitroanilide (Leu-pNA) 
rather than Leu-AMC, which exhibits significant inner filter effect at 
concentrations greater than 500µM[45]. Compound 3 activates Leu-pNA 
hydrolysis at sub-KM substrate concentrations (Figure 2.8c)  as was observed for 
Leu-AMC, but compound 3 inhibits ERAP1 hydrolytic activity under conditions of 
high dipeptide substrate concentration, Interestingly, a disease-associated allele 
(K528/Q725, allele II) is preferentially inhibited with a sub-micromolar IC50, 10-
fold lower than the disease-protective allele (R528/E730, allele IV). (Table 2.1)   
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Table 2.1 
Compound 3 exhibits ERAP1 allele-specific IC50 difference. 
Several ERAP1 alleles are present in the human population, some at high 
frequency[108]. ERAP1 hydrolysis activity of leucine-p-nitroanilide was measured 
and datapoints were fit with a sigmoidal curve. Reported are representative 
derived IC50 and confidence intervals from one of two experiments. 
  
Allele SNP Frequency 
(%) 
IC50 (µM) 
528 730 mean 95% CI 
IV R E 43 3.2 2.3 – 4.4 
III R Q 0.1 1.2 0.48 – 3.1 
II K Q 27 0.34 0.21 – 0.53 
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Mechanisms of inhibition or activation 
The ERAP1-specific compounds described in this work display either 
inhibition or activation of ERAP1-catalyzed hydrolysis of dipeptide substrate 
analogs. To further assess their behavior, we analyzed the mechanism of 
inhibition of these three compounds by measuring their perturbation of ERAP1 
Leu-pNA-cleaving activity under Michaelis-Menten conditions. Under uninhibited 
conditions ERAP1 exhibits cooperative behavior for this short substrate, requiring  
modification to the equations used in data analysis. Compounds 1 (Figure 2.8a) 
and 2 (Figure 2.8b) competitively inhibit ERAP1 under these conditions (altering 
the Kprime component of the cooperative Michalis-Menten equation while not 
affecting Vmax). This indicates that binding of these inhibitors is mutually exclusive 
with substrate binding, possibly (but not necessarily) by binding ERAP1 where 
substrate also binds. 
Compound 3 exhibits much more complicated behavior, where activity is 
increased under low substrate conditions but decreases at high substrate 
concentration. (Figure 2.8c) This data was fit with a cooperative Michalis-Menten 
equation with an additional term allowing for substrate inhibition, with Vmax 
constrained to the value observed under uninhibited conditions. At increasing 
concentrations of compound 3, the Hill coefficient decreases, which may account 
for the activating behavior at low substrate concentration. Compound 3 may 
occupy the allosteric binding site with higher affinity than Leu-pNA, causing the 
apparent mitigation of the cooperative behavior. Additionally, the substrate   
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Figure 2.8 
Mechanisms of small compound alteration of ERAP1 activity. 
ERAP1 hydrolysis of dipeptide substrate Leu-pNA is altered by hit compounds. 
ERAP1 exhibits cooperative behavior for Leu-pNA hydrolysis so data were fit 
with allosteric sigmoidal models. ERAP1 allele II was used for these experiments. 
h = Hill coefficient, Vmax = maximum reaction rate, Khalf = [Leu-pNA] at 0.5×Vmax, 
KI = inhibition constant. (a) Compound 1 competitively inhibits ERAP1 Leu-pNA 
hydrolysis. Shown is representative data from one of two experiments. (b) 
Compound 2 competitively inhibits ERAP1 Leu-pNA hydrolysis. One experiment 
was performed. (c) Compound 3 induces complex behavior where ERAP1 Leu-
pNA hydrolysis is inhibited at high substrate concentration but is activated at low 
substrate concentration (on right). Data points for conditions containing 
compound 3 are fit to an allosteric sigmoidal model modified to account for 
substrate inhibition, with all curves constrained with Vmax equal to 14.78 mol pNA 
per mol ERAP1 per second (determined from unconstrained fit of activity in the 
absence of compound 3). One experiment was performed.  
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inhibition constant decreases more than 10-fold as compound 3 concentration 
increases. This results in decreased ERAP1 activity at high substrate 
concentration. Compound 3 may stabilize a form of ERAP1 that retains activity 
but is more amenable to binding Leu-pNA substrate in a nonproductive manner. 
Overall, the behavior of compound 3 does not fit in a classical mode of small-
molecule modulation. 
 
DISCUSSION 
We implemented a high-throughput screen for short substrate inhibitors and 
activators of ERAP1. Counterscreens against ERAP2 and IRAP activity and 
cheminformatic filtering removed promiscuous compounds and identified three 
ERAP1-specific hit compounds. These all inhibited hydrolysis of a decamer 
peptide, similar in length to substrates that ERAP1 digests in vivo. Two 
compounds also inhibited ERAP1 activity in a cellular assay. 
Compounds 1 and 2 are novel non-peptidomimetic ERAP1-specific inhibitors 
that bind ERAP1’s active site. The highly conserved catalytic sites among the 
oxytocinase subfamily members presents an interesting question of how these 
compounds maintain specificity while acting as short substrate inhibitors. 
Docking shows that compound 1 contacts domain IV, which is more variable 
among the oxytocinase subfamily. Compound 2 contacts domain II primarily, 
where the active site is located, and interacts directly with the active site zinc 
atom. However, compound 2 is long enough that it extends 14.8Å from this zinc 
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atom, interacting with ERAP1 residues outside the catalytic site. These binding 
modes suggest that specificity may be attained by binding, at least partially, 
outside the active site. 
The discovery of compound 3 identifies the first non-peptide small molecule 
that allosterically activates ERAP1 hydrolysis activity of Leu-AMC. Previous work 
showed ERAP1 Leu-AMC hydrolysis activity is increased by peptides two to eight 
amino acids long[45]. Further research will investigate if these peptides and 
compound 3 are competing for one binding site. It is possible that multiple 
allosteric sites are present in ERAP1’s large internal cavity, and activity 
measurements in the presence of mixtures of activators can determine this. A 
separate pocket in domain IV has been previously indicated as the binding site 
for peptides[75, 76]. 
Hit compound 3 is an aryl sulfonamide. Another aryl sulfonamide has been 
identified as an IRAP inhibitor, which is predicted by in silico docking experiments 
to bind the active site zinc[145, 146]. However this mode of inhibition is unlikely 
for compound 3, as it activates hydrolysis of Leu-AMC, and therefore does not 
occlude the catalytic site. Docking simulations of compound 3 identified a binding 
site 28Å from the active site zinc. This indicates that these two aryl sulfonamide 
compounds do not share a binding site, and have distinct modes of inhibition. 
The two opposite effects on Leu-AMC hydrolysis of these three compounds 
preclude at least two separate binding sites on ERAP1. Interestingly, among the 
three hit compounds, the activator 3 exhibits the highest potency for ERAP1 in all 
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assays, including a cellular assay. Since screening small molecules for 
modulation of allosteric activation identified a novel hit compound that may be 
active in vivo, we propose that designing future screens to identify activators of 
enzymes that degrade biological polymers (proteases, glycosidases, and 
nucleases) may also yield novel hit compounds inaccessible by inhibition 
screens. 
The inhibitory activity of two hit compounds in an intracellular antigen 
processing assay suggests that use of these compounds can probe the specific 
role of ERAP1 in vivo. Lack of ERAP1 activity is known to elicit a cell-mediated 
immune response[86, 87], presumably by allowing presentation of antigenic 
peptides that are normally degraded by ERAP1, but the immunological and 
possible therapeutic relevance of transient specific inhibition is not well 
understood. For example, specific ERAP1 inhibition might modulate a mounting 
immune response by temporarily disrupting the class I MHC peptidome. This 
disruption would likely impair a T-cell mediated response, which normally 
expands as T-cells recognize a peptide antigen bound to MHC. Obscuring a 
peptide antigen in this manner by altering its trimming could be beneficial if this 
T-cell response has deleterious effects, such as in psoriasis[147, 148] or 
ankylosing spondylitis[149]. M1 aminopeptidase inhibition has also been 
correlated with increased antitumor immune response, another potential field of 
interest[84]. ERAP1 expression is altered in malignancies of different tissue 
origins[83], and in cases where ERAP1 overexpression protects cancerous cells 
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from immune detection by degrading antigenic peptides ERAP1 inhibition may 
produce a productive immune antitumor response.  
 
MATERIALS AND METHODS 
Protein expression and purification 
Human ERAP1 (UniProtKB Q9NZ08 allele IV with additional SNPs Asp346 
and Arg514, and alleles II and III)[108], human ERAP2 (UniProtKB Q6P179 with 
Asn392), and mouse IRAP (UniProtKB Q8C129 lumenal domain) were 
expressed recombinantly by baculoviral infection of High Five cells grown in SFX 
serum free media (Hyclone). All ORFs contain endogenous signal sequence for 
ER translocation and C-terminal 6His tag. Three days after infection by mixing 
cells (7 x 105 cells per mL) with 1% (v/v) virus preparation, culture supernatant 
was collected by centrifugation and concentrated and buffer exchanged >100 fold 
into Ni-NTA binding buffer (50mM phosphate pH8, 300mM NaCl, 10mM 
imidazole). After filtration, His-tagged protein was captured and eluted from Ni-
NTA-agarose resin (Qiagen) in buffer containing 100mM imidazole. Enzyme 
stocks were characterized by SDS-PAGE, and by measuring Leu-AMC (ERAP1 
and IRAP) or Arg-AMC (ERAP2) hydrolysis activity. 
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High-throughput library screen 
High-throughput screen reaction conditions were 7µL per well in 1536 well 
plate format. Reactions were carried out using 20mM Tris pH 7.5, 100mM NaCl, 
0.01% (w/v) BSA, 0.4% (v/v) DMSO, 1ng/µL enzyme, and 10.7µM substrate. 
After mixing, plates were incubated for 1 hour at room temperature, and then 
fluorescence emission was measured at 450nm with 380nm excitation. Z’-scores 
ranged from 0.8-0.94, using 100µM leucinethiol as a positive control for inhibition. 
 
Confirmatory and selectivity X-AMC hydrolysis assays 
Reactions were carried out in 100µL per well in black flat-bottom 96 well 
polypropylene plates (Greiner Bio-One) in 20mM Tris pH 7.5, 100mM NaCl, 
0.01% (w/v) BSA. Enzyme (400ng ERAP1, 12.5ng ERAP2 or 40ng IRAP per 
well) and hit compounds were mixed, and then substrate (final concentration 
100µM Leu-AMC for ERAP1 and IRAP, 10µM Arg-AMC for ERAP2) was added 
to start the reaction. Fluorescence at 380/460nm was measured using a BMG 
POLARstar OPTIMA once every 10 minutes starting after addition of substrate. 
Reaction rates were quantified by calculating the rate of fluorescence change. 
Each plate contained controls with DMSO alone, or with 100µM each leucinethiol 
and DTT. All reactions were normalized using these two conditions as 100% and 
0% activity, respectively. To determine EC50, normalized datapoints were fit with 
a sigmoidal curve constrained to 100% (top) for inhibitors or 100% (bottom) for 
activators. 
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Leu-pNA hydrolysis assay 
To assay the effect of compound 3 on ERAP1 at substrate concentrations 
greater than substrate KM, we used Leu-pNA rather than Leu-AMC. Reactions 
were performed in 100µL volumes in clear polystyrene 96-well plates (Corning), 
20mM Tris pH7.5, 100mM NaCl, 0.01% (w/v) BSA. Assay conditions used 200ng 
per well ERAP1 (allele II or III or IV), 7mM Leu-pNA (with allele IV) or 7.5mM 
Leu-pNA (alleles II and III), and serial dilutions of compound 3 from 200µM to 
12nM. Absorbance at 405nm was measured at 5 minute intervals. Reaction rates 
were calculated as the rate of absorbance change. To determine IC50, datapoints 
were plotted as a function of concentration of compound 3 and fit with a 
sigmoidal curve. 
To determine modes of inhibition for the three hit compounds, ‘allele II’ 
ERAP1 (200ng per well) was assayed as before but with a range of Leu-pNA 
concentrations (5mM-39µM).  Reactions were carried out as previously 
described.  To determine inhibition constants for compounds 1 and 2, data 
curves were fit globally to a competitive inhibition Michalis-Menten equation 
modified to account for cooperative behavior: 
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Figure 4. Small molecules that induce closing have altered activity for ERAP1 variants, while those that maintain 
the open conformation do not differ in behavior with ERAP1 variants.  a, Compound 2 does not show ERAP1 
variant specific potency.  Data was analyzed using a modified Michaelis-Menten model that fits both competitive 
inhibition and allosteric parameters. (shown in b). c, Compound 3 exhibits greater potency for ERAP1 allele II 
than III than IV.  Chemical structure of 3 shown on left.  Morrison analysis of IC50 for a range of substrate 
concentrations and for each ERAP1 variant shows 3 acts as a noncompetitive inhibitor of dipeptide substrate 
hydrolysis, as IC50 does not change in relation to substrate concentration.  Allele II (with K528) shows the highest 
affinity binding to 3, while alleles with R528 (III and IV) exhibit decreased potency. 
 70 
 
Compound 3 displayed activation at low substrate concentration followed by 
inhibition at high substrate concentration, and was fit to a substrate inhibition 
model to approximate the observed behavior. 
 
Peptide hydrolysis assay 
Reactions were carried out in 50µL volumes in 96 well V-bottom plate format 
with 20mM Tris pH7.5, 100mM NaCl, 0.01% (w/v) BSA. Purified ERAP1 
(20ng/well) and hit compounds were mixed, and then substrate peptide 
(WRCYEKMALK, 10µM final concentration) was added to start the reaction. After 
ten minutes the reaction was stopped by addition of 25µL 1.2% TFA. Product 
peptide (RCYEKMALK) was quantified using RapidFire LC-MS (Agilent, Pure 
Honey Technologies) by summing the area under the curve. Each plate 
contained controls with DMSO alone, or with TFA stop solution added prior to 
adding ERAP1. All reactions were normalized using these two conditions as 
100% and 0% activity, respectively. IC50 was determined by fitting normalized 
datapoints with a sigmoidal curve constrained to 100% (top) for inhibitors or 
100% (bottom) for activators. 
 
V  = 
Vmax × Sh 
Khalfh × (1 +  Ih  + Sh) 
KIh 
S = substrate concentration 
I = inhibitor concentration 
h = Hill coefficient 
KI = inhibitor binding constant 
Khalf = S when V = 0.5 × Vmax 
Vmax = maximum catalytic rate  
a 
V  = 
Vmax × Sh 
Khalfh + Sh × (1 +  S ) 
KI 
S = substrate concentration 
h = Hill coefficient 
 
KI = inhibitory substrate binding constant 
 
Khalf = S when V = 0.5 × Vmax 
Vmax = maximum catalytic rate  
b 
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In silico Docking 
Compound structures were generated initially using the PRODRG 
server[150]. Docking simulations and energy minimization was performed using 
Maestro Schrödinger version 2017-2[151]. Compounds structures were prepared 
for docking using LigPrep (pH7.5 ± 0.5) and docked using Glide onto a structure 
of ERAP1 allele II based on the closed conformation, (PDB ID 2YD0[64]) which 
was prepared using Prime. A search volume of 76Å×76Å×76Å was used,  
encompassing the entire enclosed surface of ERAP1 concurrent with the active 
site (ligand diameter midpoint search volume 40Å x 40Å x 40Å). Compounds 1 
and 2 were docked without any excluded volume. Compound 3 docking enforced 
a 6Å-radius spherical exclusion volume centered on the active site zinc atom, as 
this compound is known to activate short substrate hydrolysis and so the active 
site is likely not occluded upon binding compound 3. For compound 3, twelve out 
of thirteen hits docked at the indicated pocket, with Glide scores of -4.261 to -
0.243. The remaining dock solution bound at the catalytic zinc (2.37Å at closest) 
and was ruled out based on known enzymatic activation effect. Docking solutions 
were then inspected and one solution per compound was selected for further 
energy minimization using Embrace, using the OPLS3 force field, PRCG method, 
5000 maximum iterations, gradient convergence (convergence threshold 0.05), 
energy difference mode. 
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Cellular antigen processing assay 
HeLa cells stably expressing H-2 Kb were grown to 90% confluency in 24 well 
plates and infected with recombinant Vaccinia virus containing a cassette to 
express the ovalbumin epitope SL8 (SIINFEKL) at the C-terminus of ubiquitin, or 
a cassette which contains the same epitope preceded by a ER translocation 
signal sequence and the sequence LEQLE, which are immediately N-terminal to 
the SL8 epitope in the ovalbumin sequence. Both viral strains also express GFP 
with an IRES translation start site in line with the SIINFEKL epitope ORF. At the 
time of infection, cells were treated with inhibitor. After 16-24 hours, the cells 
were pipetted off the plate and stained with 25D1 antibody specific for SL8 in 
complex with H-2 Kb, followed by Alexa Fluor 647-goat anti mouse secondary 
antibody (Thermo Fisher). Cells were then fixed in 4% formalin and analyzed by 
flow cytometry by gating on singlet GFP+ population and quantifying Alexa 647 
median fluorescence intensity (MFI). 
 
Data analysis 
Data fitting was performed using Graphpad Prism 7[152]. Structural modeling 
data was analyzed and figures were prepared using PyMOL[153]. 
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CHAPTER III 
Large-scale conformational change during ERAP1 catalysis 
explains allostery and defines mechanism of enzymatic activity 
of disease-associated polymorphism 
This chapter corresponds to a manuscript in preparation: 
Maben Z, Arya R, Das S, Georgiadis D, Stratikos E, Stern LJ. “Large-scale 
conformational change during ERAP1 catalysis explains allostery and defines 
mechanism of enzymatic activity of disease-associated polymorphism.” 
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measured SAXS data and performed data analysis. I performed crystallization 
trials, optimized hit conditions, looped crystals and collected diffraction datasets, 
and solved crystal structures. I prepared grids for electron microscopy and 
analyzed images, picked particles, and analyzed class averages. I performed 
some enzymatic assays. I performed photocrosslinking reactions and analyzed 
final LC-MS/MS datasets. I further analyzed in silico docking solutions (initial 
results presented in Chapter II), and performed in silico analysis of electrostatic 
interactions with position. Lastly I prepared this manuscript with input from 
coauthors. 
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ABSTRACT 
The enzyme ERAP1 contributes to the generation of antigenic peptides which 
are used by the immune system to detect disease. Previous structural studies 
determined two ERAP1 conformations by crystallography. Prior enzymatic data 
suggested that conformational alteration occurs during catalysis but the specific 
nature of this mechanism is only hypothetical. We wanted to determine the role 
of conformational exchange in the ERAP1 catalytic cycle. We measured the 
conformational state of ERAP1 and observed changes in protein conformation in 
the presence of substrates and inhibitors. Structural and enzymatic data suggest 
that active site structural reconfigurations are physically linked to the closing 
step, providing a mechanism for allostery. Polymorphism at position 528 alters 
the stability of the closed state by affecting the energetics of an interdomain 
electrostatic interaction. These results clarify the steps required in ERAP1 
catalysis and demonstrate the importance of conformational dynamics within the 
catalytic cycle. 
 
INTRODUCTION 
An aminopeptidase designated endoplasmic-reticulum aminopeptidase 1 
(ERAP1) is a key determinant of antigen processing and presentation. In this 
role, ERAP1 activity digests peptides that bind to major histocompatibility 
complex (MHC) proteins in a process that both creates and destroys peptides 
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before presentation to T cells[79]. Polymorphisms within ERAP1 correlate with 
disease incidence[127], likely within defined alleles in the human population[108]. 
The ERAP1 single nucleotide polymorphism (SNP) with the highest disease 
association is rs30187, a nonsynonymous SNP with the disease-correlated 
variant encoding lysine 528 (otherwise arginine 528)[96]. The exact mechanism 
resulting in disease correlation is unknown but the effect is highly correlated with 
the presence of specific MHC alleles[154, 155], and ERAP1 SNP rs30187 alters 
the set of peptides bound to MHC[103, 104]. In biochemical assays, 
lysine/arginine 528 substitution alters ERAP1-catalyzed hydrolysis of peptides in 
a substrate-dependent manner[101]. 
ERAP1 is a member of the M1 aminopeptidase family, which is found in all 
domains of life and plays numerous functional roles[143]. These proteins contain 
a thermolysin-like domain[156] (II) which holds the active site. The M1 
aminopeptidase family has a conserved HEAT-motif-repeat domain (IV) forming 
a bowl-shaped C-terminal structure[143]. In most crystal structures of this family  
(54 out of 69 as of October 7, 2018) domain IV is closely associated with domain 
II and forms an internal pocket that separates the active site from the bulk 
solvent. This physically blocks substrate binding and product release, and so it 
was hypothesized that these aminopeptidases change structure in order to 
accommodate these steps[143]. 
The first crystal structures of ERAP1 added some complexity to the 
mechanistic model of this protein. These structures showed two separate 
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conformations that ERAP1 adopted during crystallization, which was the first 
structural determination of one M1 aminopeptidase in two states. One matched 
the closed conformation that has been observed in other family members[64]. 
Two other crystal structures captured an open conformation, in which domain IV 
makes a somewhat-rigid-body translocation away from domain II, exposing the 
internal cavity to bulk solvent[45, 64]. Simultaneously, the active site reorganizes, 
with tyrosine 438 rotating away in a position not optimal for catalysis. This 
suggested a connection exists between conformation and catalytic activity. A 
similar motion of the catalytic tyrosine 549 was later observed in crystal 
structures of insulin-regulated aminopeptidase (IRAP)[72-74]. For the 
mammalian M1 family aminopeptidase CD13, crystallized open structures do not 
demonstrate conformation-dependent catalytic tyrosine inactivation[69], 
indicating that this may be a particular feature of the oxytocinase subfamily of M1 
aminopeptidases (consisting of ERAP1, ERAP2, and IRAP)[157]. 
A connection between the active site and a distal binding site within ERAP1 
has been theorized previously to explain ERAP1 enzymatic behavior. ERAP1 
hydrolysis of dipeptide substrates such as leucine-p-nitroanilide (Leu-pNA) 
shows allosteric behavior deviating from Michaelis-Menten parameters, 
suggesting that multiple short substrate molecules bind simultaneously[45]. 
Additionally, catalysis of short substrates is increased by the presence of short 
peptides 3-14 residues in length[158, 159]. These findings, along with data 
showing preferential hydrolysis of substrates longer than 8 amino acids[44], 
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support a model that an optimal substrate peptide simultaneously binds the 
active site and some regulatory site that activates catalysis[63]. 
We examined the conformational state of ERAP1 in solution and observed 
ERAP1 conformational changes upon substrate and inhibitor binding. Crystal 
structures of two substrate-mimic inhibitors bound to ERAP1 provide new 
snapshots of ERAP1 during the substrate-binding process, conceptually 
connecting a sensor of active site occupancy, the catalytic tyrosine, and a 
disulfide bond that acts as a fulcrum to connect 6-10Å changes near the active 
site to a ~20Å motion of domain closure. We also observed that a small molecule 
binding far from the active site at an interdomain junction induces closure. We 
propose that this site is a substrate length sensor that additionally stabilizes the 
closed state, which mechanistically indicates that the phenomenon of ERAP1 
substrate minimal length preference relates to the capacity of a substrate to 
stabilize the closed conformation. Finally, we propose that the disease-related 
polymorphic position 528 (lysine/arginine) alters ERAP1 activity by energetically 
contributing to the closed conformation as it forms a transient interdomain 
electrostatic interaction with glutamate 913. 
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RESULTS 
ERAP1 is open in solution and closes upon active site occupancy 
ERAP1 has been observed to adopt open and closed conformations in X-ray 
crystal structures[45, 64], but whether these states interconvert in solution, and 
the relevance of the conformational change to catalysis had not been 
determined. In order to begin to investigate conformational transitions of ERAP1 
in solution we used small-angle X-ray scattering (SAXS). In initial experiments 
we used ERAP1 isoform 2 allele IV (Appendix I) as previously used for structural 
characterization[45] in the presence or absence of the broad-range 
aminopeptidase inhibitors bestatin[109] or leucinethiol (LeuSH)[114], (Appendix 
II) which target the active site zinc and enzyme S1 and S1’ subsites[45, 64, 109, 
114, 134]. In the presence of either of these inhibitors, ERAP1 becomes more 
compact, with the radius of gyration Rg, decreasing by ~2Å. (Figure 3.1a) To 
investigate the effect of a more physiological substrate on ERAP1 conformation, 
we used the octamer peptide, SIINFEKL. This peptide is generated efficiently 
from longer substrates by ERAP1 in vitro[63] and in vivo[43], and itself is a 
suboptimal ERAP1 substrate[44]. In the presence of a saturating amount of 
SIINFEKL, ERAP1 adopts a closed conformation. (Figure 3.1a) 
To examine the effect of active-site occupancy on ERAP1 conformation in 
more detail, we used a tight-binding tripeptide analog DG013 (IC50 33nM[119]), 
which has a phosphinic group expected to mimic the tetrahedral intermediate that 
would form at the scissile peptide bond during catalysis. (Appendix II)   
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ERAP1 in complex with 
phosphinic pseudotripeptide 
inhibitor DG013 
ERAP1 in complex with 
phosphinic pseudodecapeptide 
inhibitor DG014 
Wavelength (Ã) 0.979 1.110 
Resolution range 41.7 - 3.312 (3.568 - 3.312) 56.06 - 2.924 (3.108 - 2.924) 
Space group P 2 21 21 P 1 21 1 
Unit 
cell 
a,b,c 125.79  548.684  589.056 56.14  234.7  132.28 
α,β,γ 90  90  90 90  93.12  90 
Total reflections 6551362 (1253960) 734382 (111650) 
Unique reflections 601903 (26412) 73472 (3002) 
Multiplicity 10.9 (10.5) 10.0 (9.1) 
Completeness (%) 74.69 (22.14) 81.65 (24.49) 
Mean I/sigma(I) 2.68 (0.57) 20.11 (0.66) 
Wilson B-factor 29.61 59.49 
R-merge 1.121 (4.643) 0.6565 (3.961) 
R-meas 1.177 (4.88) 0.6921 (4.202) 
R-pim 0.3532 (1.483) 0.2154 (1.374) 
CC1/2 0.952 (0.154) 0.861 (0.285) 
CC* 0.988 (0.517) 0.962 (0.666) 
Reflections used in refinement 449952 (26400) 60060 (3001) 
Reflections used for R-free 2123 (130) 2987 (144) 
R-work 0.2854 (0.3270) 0.1983 (0.3037) 
R-free 0.2952 (0.3608) 0.2561 (0.3855) 
CC(work) 0.725 (0.430) 0.865 (0.572) 
CC(free) 0.758 (0.240) 0.844 (0.457) 
Protein molecules per ASU 22 3 
Number of non-hydrogen atoms 155927 20671 
 macromolecules 151544 20279 
ligands 4383 138 
solvent NA 39 
Protein residues 18942 2562 
RMS(bonds) 0.004 0.005 
RMS(angles) 0.64 0.79 
Ramachandran favored (%) 95.94 94.13 
Ramachandran allowed (%) 4.06 5.52 
Ramachandran outliers (%) 0 0.35 
Rotamer outliers (%) 0.42 1.7 
Clashscore 6.27 27.32 
Average B-factor 39.46 70.7 
 macromolecules 38.99 70.67 
ligands 55.77 58.99 
solvent NA 32.77 
Number of TLS groups 1 14 
 
Table 3.1 
Crystallographic data for structures determined in this work.  Statistics for the 
highest resolution shell shown in parentheses. Both datasets were processed 
using STARANISO to account for anisotropy, which generated an ellipsoidal 
envelope to identify usable reflections. Subsequent statistical parameters such 
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as R-factors are treating ellipsoidal datasets as spherical, resulting in unusually 
large deviations from expected values. Note that the set of reflections used for R-
free calculations is capped at ~2000 based on the prior determination that this 
value is statistically sufficient[160]. 
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Figure 3.1 
ERAP1 adopts a closed conformation when bound to substrate and 
substrate-mimic inhibitors. (a) ERAP1 Rg decreases in the presence of 
saturating inhibitor and substrate, indicating ERAP1 adopts a more compact 
structure in these conditions. (b) DG013 binds ERAP1 active site. Polder map 
(gray mesh) contoured at 3.5σ shows DG013 electron density at ERAP1 active 
site. (c) DG013-bound ERAP1 crystal structure is in the closed conformation. 
Shown are cartoon or surface representations of structure with domains colored. 
Surface cutaway reveals DG013 bound at active site. (d) Representative ERAP1 
SAXS curve collected using SAXS/WAXS data collection method. Data is from 
ERAP1 reference sequence (isoform I) in the absence of inhibitor or substrate. 
Inset, Guinier plot demonstrating Rg determination using linear fit of low 
resolution scattering data (q < 0.04 Å-1) (e) DG013 induces closed ERAP1 
conformation as measured by Rg. Each point is from a separate dataset collected 
and processed individually, with error of linear fit shown. Models based on 
previously determined ERAP1 crystal structures in two conformations (2YD0 and 
g 
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3MDJ chain B) are displayed for reference above, and calculated Rg values of 
these two structures are indicated with dotted lines. (f) ERAP1 experimental 
SAXS curve shown in Figure 1B (black) overlaid with calculated SAXS curves 
generated from three structural models. A model derived from molecular 
dynamics simulation fits best. Fit residuals for these three models are shown 
below. (g) Selected ERAP1 models from MD simulation demonstrate the 
relationship between angle theta and structural conformation. Respective theta 
angles shown below. (h) DG013 induces closed ERAP1 conformation as 
measured by SAXS curve fitting to structural models from molecular dynamics. 
Models that fit experimental SAXS data with χ2 < 1 are shown as points on the 
graph, forming a distribution of models that each fit scattering data within error. 
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We determined the X-ray crystal structure of ERAP1 bound to DG013, and 
confirmed that DG013 binds as expected to the ERAP1 active site (Figure 3.1b, 
Table 3.1, Table 3.2), with the enzyme adopting the closed conformation. (Figure 
3.1c, Figure 3.2) Structural determination required special consideration as the 
X-ray diffraction dataset collected was highly anisotropic. Using the STARANISO 
webserver we processed the diffraction data to account for this anisotropic 
behavior and increased the effective resolution of the dataset. Model building 
was then aided by the high degree of non-crystallographic symmetry present in 
the asymmetric unit. (Figure 3.2) 
To facilitate detailed SAXS analysis, we used a different ERAP1 construct 
(isoform 1, allele II, Appendix I) which lacks a nine-residue unstructured C-
terminal tail and recombinant myc tag not visualized in the X-ray structure that 
complicates the matching of experimental scattering data to molecular models. 
We collected SAXS/WAXS data at beamline 16-ID at NSLS-II, Brookhaven 
National Laboratory; inclusion of wide-angle WAXS data allows direct 
measurement of the water scattering profile (maximum intensity at q = 2Å-1) 
producing high quality background-subtracted scattering curves. We initially 
compared data collected by standard SAXS or SAXS/WAXS using the low-
resolution Rg analysis. 
In the absence of inhibitors, ERAP1 in solution adopts an open conformation, 
with radius of gyration (Rg) similar to that calculated for the open conformer 
observed by X-ray crystallography, as previously reported[2]. (Figure 3.1d) We   
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ERAP1 atom 
chain A 
DG013 atom 
chain A 
Interatomic distance (Å) 
Glu 183 OE1 N09 2.5 
Gly 317 N O12 2.8 
Glu 320 OE1 N09 3.0 
Glu 354 OE2 O01 3.1 
Glu 376 OE1 O02 2.9 
Glu 376 OE2 N09 4.0 
Lys 380 NZ N36 4.0 
Phe 433 CD1 C06 3.5 
Phe 433 CE2 C05 3.5 
Tyr 438 OH O02 2.4 
ZN O02 2.5 
ZN O01 2.7 
 
Table 3.2 
Intermolecular contacts between DG013 and ERAP1, chain A (PDB ID 6M8P) 
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Figure 3.2 
ERAP1 (Δ exon 10 loop):DG013 closed crystal structure overview. 
(a) Four ASU per unit cell. (b) Ribbon view of 22 ERAP1 monomer in ASU 
colored by chain. (c) view rotated 90 degrees relative to (b), ASU consists of two 
Figure S3. ERAP1 crystal structure overviews. a-f, ERAP1 (Δ exon 10 loop):DG013 closed crystal structure 
overview. a, Four ASU per unit c ll. b, Ribbon view of 22 ERAP1 monomer in ASU colored by chain. c, rotated 90 
degre s relative to (b), ASU consists of two stacked 11mer rings, here ach 11mer ring colored green and 
magenta respectively. d, As in (C) colored as chainbow. e, s in (d) showing two monomers. f, ERAP1 monomers 
are in closed conformation, one chain shown as chainbow. 
g-j, ERAP1:DG014 open crystal structure overview. g, Asymmetric unit has three ERAP1 monomers, colored by 
chain. h, View as in (A) colored by domain. i, DG014 N-terminal homophenylalanine is bonded to active site 
residues and catalytic zinc. j, Interatomic contacts between DG014 and ERAP1. 
 
a 
b c d 
f e 
a b 
c 
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stacked 11mer rings, here each 11mer ring colored green and magenta 
respectively. (d) As in (c) colored as chainbow. (e) As in (d) showing two 
monomers. (f) ERAP1 monomers are in closed conformation, one chain shown 
as chainbow. 
 
 
  
 88 
 
observed identical Rg from samples of this isoform collected by the two methods. 
(Figure 3.1e, open circles) In the presence of DG013, ERAP1 Rg decreases by 
~2Å, an effect observed in multiple measurements and protein preparations. 
))(Figure 3.1e, yellow circles) Comparison with Rg calculated for structural 
models derived from open and closed crystal structures (PDB ID 3MDJ and 
2YD0 respectively, dotted lines in Figure 3.1e) shows that the ~2Å Rg shift upon 
ERAP1 binding DG013 is consistent with a shift of the conformational equilibria 
from open to closed. 
The improved SAXS/WAXS buffer subtraction method improves data quality 
at higher q-range, allowing higher resolution analysis in which the full range of 
scattering data are fit to experimental or computational atomic models. The full-
profile data fit better to a model based on an open crystal structure than to one 
based on the closed crystal structure. (Figure 3.1f, cyan and gray symbols) To 
explore other conformers, we used a set of 45 structural models selected from a 
molecular dynamics simulation[2] that sampled a range of opening angles theta 
54-74°. (Figure 3.1g) Of these the best fitting model had theta=67°,(Figure 3.1f, 
red symbols) similar to that of the open crystal structure, but with a lower Χ2 
value. 
To account for uncertainties in the experimental data, we considered all 
models with Χ2<1. This provided a cluster of models fitting the experimental 
ERAP1 data, with theta angles bracketing the value calculated for the open 
crystal structure. (Figure 3.1h, open symbols) When we performed the same 
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analysis for ERAP1 bound to DG013, we observed a separate cluster of models 
with smaller theta angles, similar to but slightly larger than that of the closed 
structure. (Figure 3.1h, yellow symbols) Overall, the SAXS analysis shows that 
ERAP1 adopts an open conformation in solution, and closes upon binding 
substrate or substrate-like inhibitors.  
 
Ordering of the H4a helix induced by substrate binding  
To dissect structural features related to substrate binding from those related 
to the open-closed transition, we crystallized ERAP1 in the presence of a 
decamer phosphinic inhibitor, DG014 (Appendix II) under crystallization 
conditions used previously to crystallize the open structure. (Appendix I, Table 
3.1, Figure 3.3, Table 3.3) DG014 shares DG013’s phosphinic group and N-
terminal residues but is seven amino acid residues longer, and similarly inhibits 
ERAP1 with high potency. (Figure 3.4) In solution, DG014 stabilizes ERAP1 in a 
closed conformation as does DG013. (Figure 3.5) We submit that this crystal 
structure of the substrate-analog inhibitor DG014 bound to open-conformation 
ERAP1 is an intermediate step in substrate binding, which is prevented from 
proceeding to the closed conformation by stabilization through crystal packing. 
 The X-ray crystal structure shows that DG014 binds as expected with the 
phosphinic group at the active site, with only the first five residues sufficiently 
structured to allow confident modeling, and ERAP1 in the open conformation. 
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(Figure 3.6a,b) Relative to previously determined structures of the open 
conformation for ERAP1 bound to bestatin[45], conformational changes induced 
by peptide binding are apparent. A region between helices 4 and 5 (residues 
426-433) that was not visualized in previous open conformation structures[45, 
64] is now ordered and forms a short helix 4a. (Figure 3.6c) Interactions between 
the hydroxyl group of the threonine at DG014 position 3 and the sidechain of 
ERAP1 aspartate 435 constrain the C-terminal end of helix 4a. (Figure 3.6d) 
Bestatin does not make this interaction and so does not stabilize helix 4a. (Figure 
3.6e) In the absence of inhibitor, aspartate 435 is unbound and helix 4a is 
disordered. (Figure 3.6f) Thus, we propose that helix 4a becomes ordered in 
conjunction with initial binding of substrate to ERAP1. 
 
Domain closure reorients the H5 helix for catalysis 
Helix 4a, once ordered, must further shift to adopt the configuration present in 
the closed structure. Phenylalanine 433 makes substantial contacts with the 
substrate P1 side chain, as observed previously in the closed-state structure of 
ERAP1 bound to bestatin[64]. In the open state, phenylalanine 433 is oriented 
away from the active site, and reorientation is required for substrate interaction. 
Conversion between the DG014-bound (open) and DG013-bound (closed) 
structures requires translation and rotation of helix 4a which brings phenylalanine 
433 in contact with substrate P1 side chain. (Figure 3.6g)   
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Figure 3.3 
ERAP1 (allele IV, isoform 2):DG014 open crystal structure overview.  
(a) Asymmetric unit has three ERAP1 monomers, colored by chain. (b) View as 
in (a) colored by domain. (c) DG014 N-terminal homophenylalanine is bonded to 
active site residues and catalytic zinc. (d) Interatomic contacts between DG014 
and ERAP1. 
  
Figure S3. ERAP1 crystal structure overviews. a-f, ERAP1 (Δ exon 10 loop):DG013 closed crystal structure 
overview. a, Four ASU per unit cell. b, Ribbon view of 22 ERAP1 monomer in ASU colored by chain. c, rotated 90 
degrees relative to (b), ASU consists of two stacked 11mer rings, here each 11mer ring colored green and 
magenta respectively. d, As in (C) colored as chainbow. e, As in (d) showing two monomers. f, ERAP1 monomers 
are in closed conformation, one chain shown as chainbow. 
g-j, ERAP1:DG014 open crystal structure overview. g, Asymmetric unit has three ERAP1 monomers, colored by 
chain. h, View as in (A) colored by domain. i, DG014 N-terminal homophenylalanine is bonded to active site 
residues and catalytic zinc. j, Interatomic contacts between DG014 and ERAP1. 
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ERAP1 atom  
chain A 
DG014 atom 
chain D 
Interatomic distance (Å) 
Glu 183 OE1 2X0 1  N10 3.1 
Ala 318 N 7GA 2  O 2.7 
Glu 320 OE2 2X0 1  N10 3.1 
Glu 354 OE1 2X0 1  O12 3.4 
Glu 354 OE2 2X0 1  O12 3.1 
Glu 376 OE1 2X0 1  O13 2.7 
Glu 376 OE2 2X0 1  N10 2.3 
Lys 380 NZ Thr 3  O 3.6 
Glu 383 OE1 Phe 4  O 3.9 
Glu 383 OE2 Phe 4  O 3.8 
Tyr 399 OH Phe 4  O 4.0 
Asp 435 OD2 Thr 3  OG1 2.4 
ZN 2X0 1  O12 2.3 
ZN 2X0 1  O13 2.2 
 
Table 3.3 
Intermolecular contacts between DG014, chain D, and ERAP1, chain A (PDB ID 
6MGQ) 
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Figure 3.4 
Phosphinic pseudopeptides inhibit ERAP1 hydrolysis of leucine-AMC. 
Shown are normalized Leu-AMC hydrolysis inhibition curves for DG013, DG014, 
and DG023. (Appendix II) Points were fit to sigmoidal functions with best fit IC50 
as reported. Representative data from one of two experiments. Note that 
apparent cooperativity of DG023 inhibition did not reproduce in subsequent 
experiments.   
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Figure S4. Compounds inhibit ERAP1 hydrolysis of leucine-AMC.  Shown are normalized activity curves 
for DG013, DG014, and DG023. Representative data from one of two experiments. 
 94 
 
 
Figure 3.5 
Phosphinic psudodecapeptide inhibitor DG014 stabilizes more closed 
ERAP1 conformation in solution. 
(a) SAXS experiments on ERAP1 (allele II) shows the protein becomes more 
compact and more similar to the closed ERAP1 conformation as determined by 
Rg, as in Figure 3.1e. (b) The SAXS curve collected in the presence of DG014 
best fits to structural models which have decreased theta angles (are more 
closed) compared to data in the absence of inhibitor, as in Figure 3.1h.  
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Figure 3.6 
Helices 4a, 5, and 4 rotate and translate between open and closed 
conformations. 
(a) DG014, cyan, is shown bound to ERAP1 active site. Polder map (gray mesh) 
contoured at 3.5σ shows DG014 density in chain A. (b) ERAP1 was crystallized 
in the open conformation with DG014. Domains I(blue), II(green), III(orange), and 
IV(magenta) are shown as cartoon. DG014 is shown as cyan spheres. (c) Helix 
4a is ordered along the bound inhibitor. Polder map (gray mesh) contoured at at 
2.8σ. (d) Asp435, immediately C-terminal to helix 4a, contacts DG014 Thr3. (e) 
Bestatin does not contact Asp435 when bound to ERAP1 active site, and helix 4a 
is unstructured (PDB ID 3MDJ). (f) ERAP1 Asp435 lacks interaction partners 
when no ligand is bound at ERAP1 active site. Helix 4a is not ordered in this 
structure(PDB ID 3QNF). (g) Helix H4a tilts and rotates between open and closed 
conformations. Helix 4a is colored as N- to C-terminal blue-red rainbow. Helix 4a 
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tilts 35° between open and closed conformations (angle between helix central 
axes, black lines). Rotation along the helix central axis is depicted using Phe433 
sidechain for reference. DG013 homophenylalanine-phosphinyl group is shown 
bound at active site zinc. Phe433 in closed conformation contacts P1 
homophenylalanine (hPhe) of DG013 in a T-shaped π-π interaction. (h) Phe433 
motion occurs in conjunction with Tyr438 repositioning. Helix 4a moves as helix 5 
twists, positioning Tyr438 for catalysis. (interaction with DG013 shown as dashed 
line) (i) Helix 5 rotation aligning Tyr438 for catalysis[64] is coupled to motion of 
helix 4 through a disulfide bond. Arrows show relative positions of central helical 
axes. (j) Helices 10 and 12 are adjacent to helix 4, and move farther between 
open and closed conformations. (k) Quantification of incident angles between 
open and closed crystal structures for the three M1 family aminopeptidases 
indicated. For PDB entries containing multiple chains, chain A was used. 
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Another key structural transition between open and closed conformations is 
the repositioning of helix 5. It was noted previously that tyrosine 438 near the end 
of helix 5 is oriented away from substrate in the open conformation, but moves 
towards the active site in the closed conformation[45, 64]. Based on mechanistic 
studies of M1 family aminopeptidases[161] and mutagenesis studies of 
ERAP1[45], tyrosine 438 is expected to play an important role in the catalytic 
mechanism by stabilizing the oxyanion that forms in the transition state with 
water attack on the scissile bonds of a peptide substrate. Indeed, in the ERAP1-
DG014 (open) complex, (Figure 3.6h, cyan) as in previous open ERAP1 crystal 
structures, tyrosine 438 is oriented away from the active site, and moves to 
interact with the peptide bond transition state mimic phosphinic group in the 
ERAP1-DG013 (closed) complex (Figure 3.6h, magenta), in a position analogous 
to the the previously determined bestatin-bound ERAP1 closed structure[64]. 
Rotation and tilt of helix 5, which repositions tyrosine 438, is coupled to 
reorientation of phenylalanine 433 and motion of the helix 4a. (Figure 3.6h) This 
mechanism connects phenylalanine 433 motion, which senses substrate 
occupancy at the S1 pocket, with tyrosine 438 motion, which optimizes the active 
site for catalysis. 
 This conformational transition that couples phenylalanine 433 and substrate 
binding to tyrosine 438 and optimization of active site configuration is regulated 
by domain closure. Helix 5 motion is transmitted to domain IV through a disulfide 
bond between residues cysteine 443 (helix 5) and cysteine 404 (helix 4). (Figure 
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3.6i) Helix 4 forms the edge of domain II, where it lies along helices 10 and 12 at 
the edge of domain IV. (Figure 3.6j) Helix 5 acts as a lever to mechanically 
connect active site occupancy with domain closure, with rotation of helix 4a at the 
N-terminal side of helix 5 is propagated to domain IV via helix 4. Helix 4 motion is 
further propagated to the domain interface with the C-terminal side of helix 5 
acting as a fulcrum. (Figure 3.6j, compare open (cyan) to closed (magenta))  The 
disulfide bond between helix 4 and helix 5 is unique to ERAP1 and ERAP2 
among the M1 family of zinc aminopeptidases and is highly evolutionarily 
conserved among ERAP1 orthologs. (Figure 3.7) For the two other M1 family 
members that have been crystallized in both open and closed conformations, 
insulin-regulated aminopeptidase (IRAP) and CD13 (also known as 
aminopeptidase N) helix 4 motion is not as coupled to motion of helix 5. (Figure 
3.6k) 
 
Allosteric activator induces domain closure, promotes catalysis 
An interesting aspect of ERAP1’s catalytic activity is its substrate-length 
dependent allosteric modulation. The N-methylated non-hydrolyzable peptide L 
(N-Me)VAFKARAF activates ERAP1 hydrolysis of single amino acid substrates 
such as leucine-amidomethylcoumarin (Leu-AMC), while inhibiting processing of 
a full-length 10-mer peptide[45]. Leu-AMC, a synthetic fluorogenic dipeptide 
substrate commonly used to assess peptidolytic activity, is digested by ERAP1 
much less efficiently than peptides greater than 8 residues in length. Additionally,   
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Figure 3.7 
Evolutionary evidence of a disulfide bond between helices 4 and 5 inducing 
substrate length dependent aminopeptidase activity in ERAP1 and ERAP2. 
(a) ERAP1 and ERAP2 alone among M1 family zinc aminopeptidases have a 
disulfide bond linking H4 and H5. Sequence alignment of domain II of M1 zinc 
aminopeptidases in Homo sapiens. PSA, puromycin-sensitive aminopeptidase. 
(b) Phylogram of M1 zinc aminopeptidases in Homo sapiens. (c) ERAP1 H4-H5 
disulfide is evolutionarily conserved. Sequence alignment of domain II of ERAP1 
from selected model organisms.  Alignments were performed using Clustal 
Omega[162] and UniprotKB protein sequence designations. (IRAP gene name is 
LNPEP, CD13 gene name is aminopeptidase N) 
  
IRAP 
CD13 
Puromycin-Sensitive Aminopeptidase 
Glutamyl Aminopeptidase 
ERAP1 
ERAP2 
Figure S6. Evolutionary evidence of a disulfide bond between helices 4 and 5 inducing substrate length 
dependent aminopeptidase activity in ERAP1 and ERAP2. A, ERAP1 and ERAP2 alone among M1 family zinc 
aminopeptidases have a disulfide bond linking H4 and H5. Sequence alignment of domain II of M1 zinc 
aminopeptidases in Homo sapiens. B, Phylogram of M1 zinc aminopeptidases in Homo sapiens.   C, ERAP1 H4-
H5 disulfide is evolutionarily conserved. Sequence alignment of domain II of ERAP1 from selected model 
organisms.  All alignments were performed using Clustal Omega and UniprotKB protein sequence designations. 
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peptides that are too short to be processed efficiently themselves activate 
processing of other suboptimal short substrates. For example, the hexapeptide 
INFEKL inhibits ERAP1 processing of full-length peptide, but activates 
processing of shorter peptides, thus shifting ERAP1 length specificity so that it 
preferentially trims 4-6 residue peptides over 10-12mers[45]. 
These data were interpreted in terms of a mechanism whereby the allosteric 
modulators bind within the overall substrate-binding cavity, inducing conversion 
to an active conformation[45]. To investigate the relationship between 
conformational states in solution and allosteric modulation of ERAP1 enzymatic 
activity, we characterized ERAP1 bound to a non-peptidomimetic small molecule 
allosteric modulator of ERAP1, compound 3) (see Chapter II). (Figure 3.8a) 
Compound 3 inhibits ERAP1 hydrolysis of a decamer peptide, (Figure 3.8b) yet 
acts as an allosteric activator of ERAP1 and increases hydrolysis activity of the 
dipeptide substrate Leu-AMC. (Figure 3.8c) By SAXS/WAXS we observed that 
compound 3 induced a closed conformation in solution. Rg and theta values for 
ERAP1 bound to compound 3 were similar to those for ERAP1 bound to DG013 
and the other small molecule inhibitors (Figure 3.8d-f). This implicates the closed 
conformation as the induced ‘active conformer’ hypothesized to explain minimal 
substrate length preference and allosteric activation of short substrates. 
We also probed the effect of compound 3 on ERAP1 conformation by 
negative-stain electron microscopy (NS-EM), which allows for observation of 
protein conformation by a method complementary to scattering and diffraction   
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Figure 3.8 
An allosteric small molecule compound 3 induces ERAP1 domain closure 
and promotes catalysis. 
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(a) Structural formula of compound 3. (b) Compound 3 inhibits long peptide 
hydrolysis. Substrate 10mer peptide has sequence WRCYEKMALK. 
Quantification of product peptide (RCYEKMALK) by LC-MS and summing area-
under-curve (AUC) shows inhibition in product formation in the presence of 
compound 3. Data was normalized to uninhibited condition, datapoints shown are 
duplicate measurements from two separate experiments. (c) Compound 3 
activates hydrolysis of dipeptide substrates leucine-p-nitroaninide (Leu-pNA) and 
leucine-amidomethylcoumarin (Leu-AMC) Shown are representative data from 
one of several experiments. (d-f) ERAP1 adopts closed conformation in the 
presence of compound 3, as measured by (d) Rg analysis, and (e) fitting to MD 
models. (f) Residual plot of best structural model fit to SAXS data in the presence 
of compound 3, with crystal structure model fits shown for reference. (g) Selected 
2D class averages (4 out of 32, top panels) from negative stain electron 
microscopy (NS-EM) on ERAP1 aligned with 2D projections of MD models 
previously used for SAXS analysis (bottom panels). (h) NS-EM datasets of 
ERAP1 alone (black) or in the presence of saturating 3 (blue). Contingency table 
analysis comparing number of particles ≥60° vs. <60° shows a significant 
difference in the distribution of ERAP1 conformation between presence and 
absence of compound 3. (p < 1×10-15, Χ2 = 895, N = 52019, df = 1) 
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Figure 3.9 
NS-EM 2D class average model fitting 
ERAP1 NS-EM 2D class averages fit best to MD models. (on left)  Models 
generated from crystal structures (on right) fit with worse scores.  Plotted are 
best fit scores for 2D class averages generated from particles of ERAP1 with no 
inhibitor (black) or in the presence of saturating 3 (blue). Ideal fit score is -1. 
  
Figure S7. ERAP1 NS-EM 2D class averages fit best to MD models. (on left)  Models generated from crystal 
structures (on right) fit with worse scores.  Plotted are best fit scores for 2D class averages generated from 
particles of ERAP1 with no inhibitor (black) or in the presence of saturating 3 (blue). Ideal score is -1. 
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Figure 3.10 
ERAP1 closes at pH lower than 7. 
SAXS data was collected for ERAP1 isoform 2 construct (as in Figure 3.1a) with 
a range of pH conditions using citrate buffer (pH 5,6) or Tris buffer (pH 7,8,9).  
Aggregation observed at pH 5 likely occurred as ERAP1 transitioned through its 
isoelectric point (calculated pI = 5.7[163]). 
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Figure S8. ERAP1 closes at pH lower than 7.  SAXS data was collected for ERAP1 isoform 2 construct (as in 
Figure 1A) with a range of pH conditions using citrate buffer (pH 5,6) or Tris buffer (pH 7,8,9).  Aggregation 
observed at pH 5 likely occurred as ERAP1 transitioned through its isoelectric point (calculated pI = 5.7) 
(ProtParam, ExPASy) 
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methods[164]. Observed particles were grouped into 2-D class averages and 
aligned with 2-D projections of models derived from crystal structures and 
molecular dynamics simulation[164], as in the SAXS fitting, (Figure 3.8g, Figure 
3.9) A histogram of particle count as a function of model opening angle theta 
shows a bimodal conformation distribution, with closed and intermediate-open 
conformations populated similarly in the absence of compound 3. (Figure 3.8h) 
The closed conformation of ERAP1 is favored at acidic pH, (Figure 3.10) and the 
low pH of the negative stain reagent uranyl formate may alter the distribution of 
open and closed states for ERAP1 particles observed by NS-EM, increasing the 
population of closed states at a single molecule level. Despite this, in the 
presence of compound 3, ERAP1 even further populates the closed conformation 
relative to the ensemble in the absence of compound 3, as observed by NS-EM. 
(Figure 3.8h) 
We were not able to localize the site(s) of compound 3 binding to ERAP1 by 
X-ray crystallography, but an unguided in silico docking experiment placed 
compound 3 in a pocket at the junctions of domains II, III, and IV within a closed 
conformation ERAP1 model (see Chapter II). (Figure 3.11a,b) The pocket 
changes geometry between the open and closed conformations with more 
residues contacted (compare Figure 3.11a and 3.10c) and greater interface 
surface area (Figure 3.11d) for the closed conformation[165]. We propose that 
occupancy of this site preferentially stabilizes the closed conformation, which 
allosterically stabilizes helix 4a and positions phenylalanine 433 and tyrosine 438    
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Figure 3.11 
Analysis of in silico compound 3- binding pocket. 
domain ERAP1 residue 
II 
Glu409 
Leu413 
III Lys551 
IV 
Phe644 
Gln645 
Ser648 
Glu679 
Pro682 
Met683 
Lys685 
Leu686 
Arg831 
Asn880 
Gln881 
Thr914 
Glu917 
Asn918 
Trp921 
i ure S9. Analysis of in silico compound 3- binding pocket. a, Table of ERAP1 residues that form compound 3-
bi ding pocket i  closed ERAP1 str cture (base  on PDB 2YD0). (within 4Å) b, Structural model showing 
compound 3(stick representation with compound 3 carbons colored blue) with surrounding ERAP1 residues listed 
in (a). c, Table of ERAP1 residues that form compound 3-binding pocket in open ERAP1 structure (PDB 3MDJ 
chain A aligned with domain IV of closed structure). (within 4Å) d, Interface surface area between compound 3 
and ERAP1 is greater for closed structure, as determined by PISA(ref). 
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Interface area (Å2) 
ERAP1 compound 3 
closed 151.3 252.6 
open 126.3 242.2 
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(a) Table of ERAP1 residues that form compound 3-binding pocket in closed 
ERAP1 structure (based on PDB 2YD0). (within 4Å) (b) Structural model showing 
compound 3(stick representation with compound 3 carbons colored blue) with 
surrounding ERAP1 residues listed in (a). (c) Table of ERAP1 residues that form 
compound 3-binding pocket in open ERAP1 structure (PDB 3MDJ chain A 
aligned with domain IV of closed structure). (within 4Å) (d) Interface surface area 
between compound 3 and ERAP1 is greater for closed structure, as determined 
by PISA[165]. 
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to bind and hydrolyze substrate. This mechanism of stabilizing the active site of 
ERAP1 allosterically though conformational change would explain the activating 
effect compound 3 has on suboptimal short substrate activity. 
 
Peptide C-terminus binding sites localize within domain IV 
ERAP1 exhibits side chain specificity at the C-terminal as well as N-terminal 
end of peptide substrates, suggesting contact (s) occur between enzyme and 
substrate beyond the five residues of DG014 for which ordered peptide density 
was observed. To identify peptide C-terminal binding sites, we used a 
photocrosslinking approach. We developed a crosslinker probe peptide inhibitor, 
designated DG023, consisting of a peptide sequence based on an ERAP1 
substrate[101] but with the nonhydrolyzable phosphinic group replacing the first 
peptide bond, and the unnatural amino acid p-benzoyl-L-phenylalanine (BPA)-
amide at the C-terminus[166]. (Figure 3.12a) UV irradiation (350nm) of BPA 
generates a carbene that can form a covalent bond with nearby molecules[166]. 
This compound inhibits ERAP1 hydrolysis activity. (Figure 3.4) We performed 
crosslinking reactions in this manner using DG023 and purified ERAP1, and 
identified three crosslinking sites by LC-MS/MS. (Figure 3.12b, Figure 3.13, 
Figure 3.14, Figure 3.15, Figure 3.16) Two of the sites, leucines 677 and 838, lie 
in domain IV next to a subsite previously identified as a possible site of substrate 
peptide C-terminal binding by X-ray crystallography[64, 75, 76]. (Figure 3.12c) 
The third site, leucine 686, borders domains II, III, and IV at the in silico docking   
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Figure 3.12 
Substrate C-terminus binding sites identified by crosslinking. 
(a) Crosslinker peptide sequence is based on sequence of characterized ERAP1 
substrate[101]. First two amino acids are phenylalanine and leucine analogs 
connected by a phosphinic group ‘p’[119]. Peptide C-terminus bears a 
photocrosslinker p-benzoylphenylalanine (Bpa)[166]. After crosslinking, trypsin 
cleaves probe peptide leaving Bpa-amide as a 268 Da adduct at the crosslink 
site. (b) Crosslinked ERAP1 residues reside in domain IV, magenta surface. 
Orthogonal views shown of closed ERAP1 structure(PDB ID 2YD0). Crosslinked 
amino acids shown as sticks with colored boxes. On right, a cutaway view 
(cutaway plane indicated by dotted line on left) reveals crosslink sites as red 
surface. (c) Close views of modeled Bpa-amide in proximity to crosslinked 
ERAP1 leucines 838 and 677, labeled on left and shown in red. (d) Close view of 
modeled Bpa-amide in proximity to crosslinked ERAP1 leucine 686, as in (c). 
This pocket is formed between domains II, III, and IV. (green, orange, magenta 
surface respectively) (e) Compound 3 docked in silico to same interdomain 
pocket shown in (d) 
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L838 
L677 
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L686 
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Crosslinker peptide: 
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 110 
 
 
 
Figure 3.13 
Crosslinked ERAP1 tryptic digest fragments identified by LC-MS/MS. 
Identified peptides are highlighted gray, yellow, or cyan.  Crosslinked leucine 
residues are boxed. 
 
  
Figure S8. Crosslinked ERAP1 tryptic digest fragments identified by LC-MS/MS.  Identified peptides are 
highlighted gray, yellow, or cyan.  Crosslinked residues are boxed. 
MVFLPLKWSLAIMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRLPEYVIPVHYDLLIHANLTTLTFWGTTK
VEITASQPTSTIILHSHHLQISRATLRKGAGERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGF
YKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPLVKSVTVAEGLIEDHFDVTVKMS
TYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGL
TTYRESALLFDAEKSSASSKLDITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKVGDYFFGKCF
DAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASIC
PTDGVKGMDGFCSRSQHSSSSSHWHQERVDVKTMMNTWTLQRGFPLITITVRGRNVHMKQEHYMKGSDGAPDTGYLWHVPL
TFITSKSDMVHRFLLKTKTDVLILPEEVEWIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVS
IGKLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLIDKQTWTDEGSVSERMLRS
ELLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQN
KEKLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHMVMGTTNQFSTRTRLEEV
KGFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFDKIRVWLQSEKLEHDPEADATGLERMLESRGPFEQKLISEEDLNMH
TEHHHHHH 
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Figure 3.14 
ERAP1 peptide 666-685 crosslink identification. 
(a) Peptide identification parameters. (b) MS/MS spectra. (c) Fragmentation 
table. All data generated from Scaffold4 output. 
  
ERAP1 amino acids 666-685 
crosslink on Leu677 
MS1 intensity = 9.16e6 
665.08 m/z 
+4 charge 
SEQUEST Xcorr = 2.38 
SEQUEST deltaCn = 0.45 
peptide probability = 99% 
Figure S10. Crosslinked ERAP1 tryptic digest fragments identified by LC-MS/MS.  a, Identified peptide sequences 
within ERAP1 are highlighted gray, yellow, or cyan.  Crosslinked residues are boxed. b, MS/MS spectra and 
fragmentation tables for crosslinked ERAP1 peptides generated from Scaffold4, colored as in (a). 
 
a 
c 
b 
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Figure 3.15 
ERAP1 peptide 666-689 crosslink identification. 
(a) Peptide identification parameters. (b) MS/MS spectra. (c) Fragmentation 
table. All data generated from Scaffold4 output. 
  
ERAP1 amino acids 666-689 
crosslink on Leu686 
MS1 intensity = 1.48e6 
638.92 m/z 
+5 charge  
SEQUEST Xcorr = 2.10 
SEQUEST deltaCn = 0.11 
peptide probability = 75% 
Figure S10. Crosslinked ERAP1 tryptic digest fragments identified by LC-MS/MS.  a, Identified peptide sequences 
within ERAP1 are highlighted gray, yellow, or cyan.  Crosslinked residues are boxed. b, MS/MS spectra and 
fragmentation tables for crosslinked ERAP1 peptides generated from Scaffold4, colored as in (a). 
 
b 
c 
a 
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Figure 3.16 
ERAP1 peptide 829-854 crosslink identification. 
(a) Peptide identification parameters. (b) MS/MS spectra. (c) Fragmentation 
table. All data generated from Scaffold4 output. 
  
ERAP1 amino acids 829-854 
crosslink on Leu838 
 MS1 intensity = 3.48e7 
832.20 m/z 
+4 charge 
SEQUEST Xcorr = 4.57 
SEQUEST deltaCn = 0.48 
peptide probability = 100% 
Figure S10. Crosslinked ERAP1 tryptic digest fragments identified by LC-MS/MS.  a, Identified peptide sequences 
within ERAP1 are highlighted gray, yellow, or cyan.  Crosslinked residues are boxed. b, MS/MS spectra and 
fragmentation tables for crosslinked ERAP1 peptides generated from Scaffold4, colored as in (a). 
 
b 
c 
a 
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site identified for compound 3. (Figure 3.12d) The homologous site is accessed 
by long peptides bound to mammalian aminopeptidase N (CD13), a structural 
homolog of ERAP1 involved in neuropeptide processing[71]. The leucine 686 
pocket changes geometry between the open and closed conformations as noted 
previously (Figure 3.11) with greater buried surface area observed for the closed 
conformation[165]. Increased buried surface area correlates with greater 
energetic stability by decreasing the energetic requirement of solvation[165], and 
in this case the energetic contribution of binding differs between two 
conformations. We propose that this interdomain site bordered by leucine 686 is 
a novel peptide C-terminus binding site of ERAP1. We propose that occupancy 
of this site by a ligand such as a portion of a peptide substrate or allosteric 
modulator such as compound 3 promotes ERAP1 catalytic activity by increasing 
the energetic stability of the closed conformation.  
 
Lys/Arg 528 SNP alters domain closure, regulates activity 
Numerous genome-wide association studies (GWAS) have linked a common 
ERAP1 polymorphism at position 528 with incidence of diseases such as 
psoriasis, Behçet’s disease, and most strongly, with ankylosing spondylitis[96, 
155, 167]. The disease-correlated variant codes for lysine at this position, 
compared to arginine in the protective ERAP1 allele. This seemingly 
conservative substitution nevertheless has an effect on immune function, 
presumably by altering the presentation of a peptide that stimulates an 
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autoimmune response[103]. Proposed mechanisms for this effect include 
alterations in protein expression[168] (although this may be due to linkage with 
other SNPs and not directly resulting from rs30187[169]) and altered protein 
conformational flexibility[159].  
As reported previously[101, 159], we find that arginine 528 distinctly alters 
enzymatic activity compared to lysine 528, increasing the enzyme catalytic rate 
(kcat) but decreasing apparent substrate affinity (KM). (Figure 3.17) This trend is 
similar, albeit with lesser magnitude, to that observed when mutations that 
disrupt interdomain salt bridges were introducted into ERAP1[2]. Examination of 
the ERAP1 structure and electrostatic calculations show that a positively charged 
residue at position 528 forms a long-range electrostatic interaction with glutamate 
913 in domain IV. This interaction would contribute preferentially to the closed 
conformation, as the pair of amino acids moves far apart in the open 
conformation. (Figure 3.17b) Calculation of the electrostatic potential between 
positions 528 and 913 shows that arginine 528 has a weaker energetic 
contribution to the closed conformation than lysine 528. (Figure 3.17c) These 
data supports a mechanism where the closed conformation is required for 
catalysis and ERAP1 variants with arginine 528 are less able to access this 
conformation due to the loss of a stabilizing interdomain interaction. 
If this model is correct, one prediction is that inhibitors which stabilize the 
closed conformation of ERAP1 would have weaker affinity for arginine 528 than 
lysine 528, while inhibitors that do not stabilize the closed ERAP1 conformation   
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Figure 3.17 
Substitution at position 528 (lysine or arginine) alters ERAP1 activity by 
making a conformationally-dependent interdomain electrostatic interaction. 
(a) Substitution at position 528 alters ERAP1 activity. Shown is combined data 
(Lys528, 6 experiments. Arg528, 4 experiments) globally fit to an allosteric 
sigmoidal curve. Fit parameters are shown in table below. Asterisks indicate 
statistical significance by extra-sum-of-squares F test. ( * = p < 0.05, ** = p < 
0.0001) (b) Position 528 makes a long-distance electrostatic interaction with 
glutamate 913. The interaction brackets asparagine 414. N-acetyl-glucosamine in 
crystal structure shown in gray. Views shown are in closed and open 
conformations. Closest interatomic distances between Lys/Arg528 and Glu913 
are 7.6Å(closed) and 13.6Å(open), respectively. (c) Lys528 stabilizes closed 
ERAP1 conformation more than Arg528. Pairwise electrostatic potential between 
residues 528 and 913 shown in gray highlight. Potential energy was calculated 
using DelPhiForce webserver. Models for input were generated using PDB ID 
2YD0 (Lys528/closed) or 3MDJ chain A (Arg528/open) and computationally 
mutating position 528 to complete the matrix. 
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should have equivalent affinity for the two variants. This trend was observed 
when aforementioned artificial electrostatic mutations were introduced into 
ERAP1 and the resulting proteins demonstrated differential inhibition by 
DG013[2]. We found that a small-molecule inhibitor, compound 2(see Chapter II), 
(Figure 3.18a) does not close ERAP1 when present at saturating concentrations. 
(Figure 3.18b) We observed equivalent potency of this inhibitor for the two 
ERAP1 variants (lysine/arginine 528). (Figure 3.18c) In contrast, DG013 (Figure 
3.18d) and compound 3 (Figure 3.18e) both affect lysine 528 ERAP1 with greater 
potency (lower IC50/AC50 respectively) than arginine 528 ERAP1. While 
compound 2 and DG013 both act as inhibitors of the short substrate Leu-AMC 
used in these experiments, their inhibition mechanisms are distinct due to their 
differential conformational effect. The differential affinity of ERAP1 arginine 528 
and lysine 528 variants for compounds that preferentially stabilize the closed 
state (DG013 and compound 3) are consistent with a model that ERAP1 domain 
closure is altered by polymorphic variation at position 528. 
 
DISCUSSION 
Together these data let us build a more complete mechanistic model of 
ERAP1 catalysis. (Figure 3.19) In this conceptualization, ERAP1 begins in the 
open state, with helix H4a unstructured (EO). Substrate binds this state (EOS), 
H4a ordering occurs (EO’S), and then simultaneously, H4a rotates and domain IV   
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Figure 3.18 
Small molecules that induce closing have altered potency for ERAP1 
variants, while those that maintain the open conformation have equal 
potency for ERAP1 variants. 
(a) Structural formula of compound 2. (b) ERAP1 conformation remains open in 
the presence of compound 2, determined by Rg analysis and model fitting of 
SAXS/WAXS data. (c) Compound 2 does not show ERAP1 variant-specific 
potency. Leucine-AMC hydrolysis rate was measured and normalized to control 
condition without compound 2. Data was fit to a sigmoidal curve with constrained 
top and bottom = 100 and 0% activity respectively. Significance calculated using 
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two-tailed ANOVA. (d) DG013 exhibits greater potency for Lys528 ERAP1 than 
Arg528 ERAP1. Leucine-AMC hydrolysis rate was measured and normalized to 
control condition without DG013. Data was fit as in (c). Significance calculated 
using two-tailed ANOVA. (*, p<0.0001) (e) Compound 3 exhibits greater potency 
for Lys528 ERAP1 than Arg528 ERAP1. Leucine-AMC hydrolysis rate was 
measured and normalized to control condition without compound 3. Data was fit 
to a sigmoidal curve with constrained bottom = 100% activity. Significance 
calculated using two-tailed ANOVA. (*, p<0.0001) (f) Structural formula of 
compound 1. (g) ERAP1 conformation remains open in the presence of 
compound 1, determined by Rg analysis and model fitting of SAXS/WAXS data. 
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Figure 3.19 
Conceptual reaction coordinate diagram of ERAP1 catalytic cycle. 
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Figure 7. Conceptual reaction coordinate diagram of ERAP1 catalytic cycle. 
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closes (EC), with phenylalanine 433 and tyrosine 438 engaging substrate for 
hydrolysis. The reaction products (one free amino acid and the remaining 
peptide) are then released by opening (ECP  ECP) and dissociation (EO + P). In 
the absence of contrary evidence, this model depicts product dissociation as 
energetically equivalent to substrate dissociation. This assumption may not be 
valid, as the ‘register’ of the peptide bound to ERAP1 would not match between 
these two states. Alternatively, release of the hydrolyzed N-terminal amino acid 
may occur separately from release of the C-terminal peptide product. Future 
experiments are indicated to determine the nature of product release. We also do 
not know the order of binding events for long substrate peptides, which may 
engage either the allosteric C-terminal site or the active site initially. This order of 
events may even differ for substrates of differing sequences and lengths, and so 
more mechanistic studies are warranted to dissect this open question. 
Previous reports of conformational change upon substrate or inhibitor binding 
in M1 family aminopeptidases relied on indirect methods such as measurements 
of enzyme aminopeptidase activity[69] or competitive binding assays[71]. While 
useful, these results may be complicated to design and interpret. Our direct 
structural observations delineate between effects on activity and effects on 
conformation. Wider study of the relationship between conformation state and 
catalysis of M1 aminopeptidases would inform the mechanisms of the enzyme 
family and any specific features unique to the oxytocinase subfamily. 
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One caveat of using SAXS to determine conformational state in this system is 
the difficulty in distinguishing mixtures of states from single conformations. In 
theory this is possible, however the changes in scattering between open and 
closed states are relatively small within this system. We fit SAXS data to single 
molecular models, as one-model fits described the data within error (Χ2<1). 
Fitting SAXS data as a weighted ensemble of two models nominally improved the 
fit, yielding even lower Χ2 values, but this may be due to fitting of noise in the 
SAXS data and was not,in our opinion, justifiable. More sophisticated statistical 
analysis may allow further investigation of this ensemble using SAXS[170]. 
We expect that ERAP1 molecules transition throughout an energy landscape 
between open and closed states, as was defined by molecular dynamics 
simulation previously[2, 159], and that molecules in solution populate an 
ensemble of these major states, and intermediates therein, in a dynamic 
equilibrium. Electron microscopy may be used to observe protein conformation 
on a per-particle basis, and our negative stain-EM data of ERAP1 identified that 
molecules generally populate two distributions (one ‘closed’ and one ‘semi-open’) 
with conformations observed bracketing each peak, as opposed to a sharp 
distribution where each conformation is defined by a single model. This supports 
the model of a more continuous energy landscape. Cryo-EM data collection, 
which would avoid the acidic pH from negative staining with uranyl formate, 
would more closely match the buffer conditions used for SAXS and would 
provide a complementary perspective on ERAP1 conformation. 
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The prior identification of compounds 2 and 3 as nonpeptidomimetic ERAP1-
specific inhibitors opened questions regarding their mechanism of action and 
determinants of specificity. While characterization is ongoing, the conformational 
effects induced by inhibitors permits classification of three inhibition mechanisms: 
(1) inhibition by substrate mimicry (bestatin, leucinethiol, DG013) causing closed 
conformation stabilization, (2) inhibition by open conformation stabilization 
(compound 2), and (3) allosteric inhibition by closed conformation stabilization 
(compound 3). Cocrystallization of IRAP with a phosphinic peptidomimetic 
inhibitor stabilized a closed structure[72], consistent with mechanism (1). 
Development of small molecule M1 aminopeptidase inhibitors that utilize other 
inhibition mechanisms may be possible, but would require concerted exclusion of 
peptidomimetic moieties which are a principle focus of rational inhibitor design in 
the field currently[143]. 
Our data describes a mechanism where polymorphism at position 528 
(lysine/arginine) alters ERAP1 enzymatic activity by changing the opening rate of 
the closed conformation. In this case, ERAP1 containing lysine 528 has a slower 
opening rate than arginine 528. Conformational effects of polymorphisms have 
been proposed previously based on MD simulations of ERAP1 variant 
conformation[159]. These previous in silico studies support a model where 
arginine 528 ERAP1 does not adopt as wide an open conformation as lysine 528, 
and instead converts between ‘closed’ and ‘semi-closed’ states. Our SAXS data 
of these two variants finds no appreciable difference in conformation state due to 
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substitution of position 528, with both adopting an open conformation. In the 
presence of saturating concentrations of small molecules, the two variants 
changed conformation in the same manner and to the same degree. Using 
inhibitor potency as a probe, we found evidence that the key difference between 
variants at position 528 is not the equilibrium state at saturation but in the rates of 
exchange within that equilibrium. 
Direct observation of rates of conformational change would further test this 
model. This is possible using techniques such as continuous flow time-resolved 
SAXS (trSAXS) where ERAP1 and a ligand (substrate, inhibitor, or activator) flow 
continuously through a mixing chamber and X-ray scattering data is measured at 
particular locations along the flow path, which are correlated with post-mixing 
time as determined by the solution flow rate[171]. This technique requires large 
quantities (tens of milligrams) of protein, which currently limits application of 
trSAXS to this project. Alternatively, spectroscopic techniques such as single-
molecule Forster resonance energy transfer (FRET) might permit the observation 
of conformational exchange rates. This method requires coupling fluorescent 
probes to ERAP1 which may alter ERAP1 activity, and so is not without its own 
caveats. 
The consequence of an enzyme enclosing a substrate, such as occurs with 
M1 aminopeptidases, is an effective increase in substrate binding affinity by 
kinetically trapping the substrate into the active site. For substrates that innately 
exhibit affinity to bind the open form, alteration of this trapping step (such as an 
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increased opening rate, as we predict for ERAP1 arginine 528 relative to lysine 
528) would have little effect on apparent affinity. For substrates with lower 
affinity, however, a faster opening rate may allow substrate dissociation. We 
predict that the reported decreased activity of arginine 528 ERAP1 is 
exacerbated for substrates with weaker substrate affinity for the open 
conformation. 
Our findings still do not explain the role that other polymorphic sites play. 
Some sites such as position 127 (arginine/proline) lie near domain junctions, and 
may contribute to conformation. Other polymorphic sites such as the important 
position 730 (glutamine/glutamate) are far from interdomain regions and may 
alter ERAP1 activity by a separate mechanism, possibly related to substrate 
binding. The possibility and potential utility of inhibiting particular ERAP1 alleles 
in vivo remains to be seen, but in heterozygous patients with ankylosing 
spondylitis[96] or psoriasis[99, 172](lysine 528 increases risk of incidence of both 
diseases), this might modulate the underlying immune reaction by disrupting 
antigen processing. Great care should be taken when adjusting immune 
reactions in this manner, but the benefit may outweigh the risk[173]. 
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MATERIALS AND METHODS 
Mutagenesis and baculovirus production 
Sequence variants of ERAP1 were generated as gene cassettes in pFastBac 
plasmid using Agilent QuikChange II XL site-directed mutagenesis. Positive 
clones were used to make bacmids and baculoviral stocks were prepared 
following Bac-to-Bac baculoviral system protocol. 
 
Protein expression and purification 
High Five cells were infected with baculoviral stocks and cultured for three 
days at 27C. Cells were then pelleted and supernatant was concentrated to 
~100mL and buffer exchanged >100-fold into 50mM Tris pH8, 300mM sodium 
chloride, 10mM imidazole. Samples were bound to Ni-NTA-agarose resin, 
washed with 10mM imidazole buffer, then washed with 20mM imidazole buffer, 
then eluted with 100mM imidazole buffer. Samples were then purified by anion 
exchange chromatography and size exclusion chromatography.  
 
Chemical synthesis 
Synthesis of phosphinic peptide DG013: Phosphinic pseudopeptide DG013 
was synthesized as described previously[119]. 
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Synthesis of phosphinic peptide DG014: Phosphinic pseudopeptide DG014 
was synthesized by applying standard solid phase peptide synthesis, on trityl 
alcohol lanterns (15 µmol/pin) using a Fmoc chemical protocol. A solution of 
acetyl chloride in dry dichloromethane (1:10 v/v) at room temperature was used 
to afford the trityl chloride lanterns. Attachment of the first aminoacid Fmoc-Tyr 
(tBu)-OH (30 µmol/pin) was performed by using N,N-diisopropylethylamine (18 
µL/pin) in dry dichloromethane (0.4 mL/pin) at room temperature for 12 h.[174] 
The loading amount of Fmoc-Tyr (tBu)OH was evaluated to be 12 µmol/pin, after 
cleavage from the polymer-support with 0.5% trifluoroacetic acid 
(TFA)/dichloromethane (room temperature, 1h). Fmoc deprotection was 
performed with a solution of 20% piperidine in N,N-dimethylformamide over 1h 
for each cycle of the synthesis. Fmoc protected aminoacids (45 µmol/pin), 1-
hydroxybenzotriazole (45 µmol/pin) and diisopropylcarbodiimide (45 µmol/pin) in 
dichloromethane/N,N-dimethylformamide (6/1) (0.4 ml/pin), were used for the 
coupling steps and each coupling reaction was allowed to proceed for 5h. 
Coupling of the building block Boc- (R)hPhep[PO (OAd)CH2] (R,S)LeuOH (23 
µmol/pin)[119], was performed using the coupling conditions described above (36 
µmol/pin of each reagent). Deprotection and removal of the final 
pseudodecapeptide from the solid support was accomplished by using a solution 
of TFA/dichloromethane/triisopropylsilane/H2O 39/58/2/1 for 2h at room 
temperature. After concentration in vacuo, the crude product was precipitated in 
cold diethyl ether. DG014 was obtained after purification by analytical RP-HPLC 
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and characterized by mass spectroscopy [ESMS m/z (z = 1): calcd for 
[C62H90Ν9Ο18P+H]+ 1281.4; found: 1281.5]. 
Synthesis of phosphinic peptide DG023: The phosphinic 
pseudoundecapeptide DG023 was prepared by conventional solid-phase peptide 
synthesis, on Rink amide lanterns (8 µmol/pin), using the Fmoc strategy. Fmoc 
deprotection and aminoacid coupling steps were performed as described above 
for DG014. After the introduction of Fmoc-Bpa-OH all synthetic steps were 
performed in light-protected conditions. For the introduction of phosphinic 
pseudodipeptidic sequence, the building block Boc- (R)Phe[PO (OAd)CH2] 
(S)LeuOH was synthesized in three steps starting from the R-stereoisomer of the 
Boc-protected aminophosphinic analog of phenylalanine[158, 175]. The 
phosphinic pseudodipeptide Boc (R)Phe)[PO (OH)CH2] (S)LeuOEt was prepared 
as previously described[176], and obtained in a stereochemically pure form after 
2 recrystallizations with AcOEt. Subsequent adamantylation of the phosphinic 
group and saponification of the C-terminal ethyl ester group afforded the final 
building block Boc (R)Phe[PO (OAd)-CH2] (S)LeuOH[176], which was 
incorporated in the last step of the solid phase synthesis. For the coupling of the 
aforementioned building block, 16 µmol/pin were used by using standard 
coupling conditions. The final pseudoundecapeptide was cleaved and 
deprotected from the solid support in presence of a solution of trifluoroacetic acid 
(TFA)/H2O/triisopropylsilane 95/2.5/2.5 over 2 h at room temperature. The 
solution of deprotected peptide was concentrated in vacuo and the residue was 
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treated with cold dry diethyl ether. DG023 was obtained after purification by 
analytical RP-HPLC and characterized by mass spectroscopy [ESMS m/z (z = 1): 
calculated for [C79H104Ν17Ο14P +H]+ 1546.8; found: 1546.9]. 
 
Small angle X-ray scattering data collection 
Purified protein samples were mixed with inhibitor, if indicated, and 
concentrated in rinsed Centricon 10kDa MWCO 0.5mL centrifugal concentrators 
equilibrated in 50mM HEPES pH7.5, 200mM NaCl, 0.02% (w/v) NaN3. 
Concentrator retentate and flowthrough were stored and used as sample and 
buffer respectively during SAXS data collection. SAXS data was collected for 
each sample at three concentrations (generally 4mg/mL, 2mg/mL, and 1mg/mL). 
Small molecule additives were included at the following concentrations: 2mM 
bestatin, 30µM leucinethiol with 30µM dithiothreitol, 120µM SIINFEKL peptide, 
100µM DG013, 200µM compound 3, 200µM compound 2. 
 
Small angle X-ray scattering data processing and analysis 
Scattering curves were buffer subtracted using matched buffer scattering 
curves. The concentration series was then compared, scaled, and merged 
manually using PRIMUS[177] in ATSAS v2.5.2 and SCÅTTER (version 3.0g). 
Merged SAXS curve Rg was calculated using AutoRG. Minimal ensemble search 
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was performed using the FOXS webserver[178] with data fit to single structural 
models of ERAP1. 
 
ERAP1 structural modeling 
Structural models were generated by two methods. For models derived from 
crystal structures (PDB ID 2YD0, and 3MDJ chains A/B/C), missing portions of 
polypeptide and complete high mannose N-glycans were added by rounds of 
simulation using the AllosMod webserver[179]. Alternately, structural models 
were sampled from a prior molecular dynamics simulation of ERAP1[2]. 
 
Crystallization 
Purified protein samples were prepared in 10mM Tris or 10mM HEPES 
buffer. Crystal trials screens were set up and hits were optimized. For DG013-
bound ERAP1 cocrystal, final crystallization conditions were: sitting drop vapor 
diffusion, 1.3M ammonium sulfate, 100mM MES pH5.5, 15mg/mL ERAP1 
preincubated with saturating DG013, grown at 25C, dehydrated by changing well 
solution to 2M ammonium sulfate one day prior to looping, cryoprotected with 
lithium sulfate. For DG014-bound ERAP1 cocrystal, final crystallization conditions 
were: hanging drop vapor diffusion, 15% PEG8000, 100mM Tris pH8.60, 3% D-
sorbitol, 7.5mg/mL ERAP1 preincubated with saturating DG014, grown at 4C, 
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cryoprotected with ethylene glycol. Crystals were mounted on loops and frozen 
by plunging in liquid nitrogen in preparation for data collection. 
 
X-ray diffraction data collection 
Crystal diffraction data was collected in a 180° arc about a static crystal (PDB 
ID 6MGQ) or a 360 arc about a crystal transiting along a defined vector (PDB ID 
6M8P). X-ray wavelengths used were 1.110Å (PDB ID 6MGQ) and 0.979Å (PDB 
ID 6M8P) 
 
Structure determination  
X-ray diffraction data was integrated using XDS version June 1, 2017[180]. 
Data is highly anisotropic and so was processed using STARANISO[181]. Initial 
molecular replacement was found using 2YD0 (PDB 6M8P) or 3MDJ (PDB ID 
6MGQ) as search models. For PDB ID 6M8P, initial diffraction data was 
integrated as P212121 but did not yield MR solution in Phaser-MR[182]. Allowing 
other solutions within point group yielded solutions in spacegroup P22121 with 22 
chains placed in two 11-mer rings. For PDB ID 6MGQ, a suitable solution was 
found by searching separately for (domains I+I+III) and (domain IV). Inhibitor 
chemical structures were initially built using the PRODRG webserver[150]. 
Restraints were then generated using eLBOW[183], and models were built 
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through cycles of refinement[184] and manual rebuilding[185]. Omit maps were 
generated using Polder[186]. 
 
Enzyme activity assays 
ERAP1 activity was measured consistently in 96-well format, 100µL reactions 
containing 20mM Tris pH7.5, 100mM NaCl, 0.02% sodium azide, with 0.1% (w/v) 
bovine specific antigen (BSA) present to block ERAP1 binding to plastic 
(observed even for ‘non-binding’ polypropylene plates). For peptide hydrolysis, 
ERAP1 (0.2ng/uL) was mixed with inhibitor (25µM) and then incubated with 
substrate peptide (10µM) for 10 minutes. Reactions were stopped by addition of 
trifluoroacetic acid, 0.4% (v/v) final concentration. Plates were frozen and 
shipped to PureHoney Technologies for quantification of substrate and product 
by LC-MS and summing area-under-curve of respective peaks. 
For leucine-amidomethylcoumarin hydrolysis, ERAP1 (2ng/µL) was mixed 
with inhibitor if indicated and reactions were begun by addition of Leu-AMC 
substrate (100µM). Product formation (7-amino-4-methylcoumarin) was 
quantified by measuring change in fluorescence (380nm excitation/460nm 
emission) over 20 minutes at 25C using BMG POLARstar OPTIMA. 
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Negative stain-electron microscopy 
ERAP1 was prepared at 6µg/mL alone (in 10mM HEPES pH7.5, 200mM 
NaCl), or at 7.5µg/mL with 150µM compound 3. Protein was then blotted on 400-
mesh copper grids with Formvar /carbon film and stained with 0.75% (w/v) uranyl 
formate (pH4.5). Serial images were collected using a Tecnai F20 microscope at 
200kV (154 and 113 micrographs with and without compound 3 present, 
respectively). Images were processed using EMAN 2.21a [187]. Particles were 
picked using a neural network, yielding 19798 and 32221 particles with and 
without compound 3 present, respectively. Particles were then classified 
automatically into 32 2-D class averages and, using the “e2classvsproj” module 
within EMAN2, aligned with 2-D projections of MD models or crystal-structure-
based models used in SAXS analysis[164]. The theta value of each best model 
and the alignment score for each class average are reported in Figure 3.9. 
 
Photocrosslinking and mass spectrometry 
Purified ERAP1 (allele IV, isoform 2) was incubated in a V-bottom 96-well 
plate in the presence or absence of DG023 crosslinking peptide inhibitor (100µM 
DG023, 20µM ERAP1) and irradiated for 30 minutes on ice using a long-
wavelength UV lamp (Blak Ray B100AP/R, UVP). Samples were then denatured, 
deglycosylated enzymatically, and separated by SDS-PAGE. Excised gel bands 
were trypsin-digested and analyzed by LC-MS/MS at the UMass Proteomic Core 
Facility. Crosslinks were detected by searching the SwissProt human proteome 
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database using Sequest (IseNode from Proteome Discoverer 2.1.1.21, fragment 
ion mass tolerance of 0.050 Da, parent ion tolerance of 10.0PPM) for a +268 Da 
modification on leucine, serine, tryptophan, or methionine. One identified 
crosslinked ERAP1 peptide was excluded from analysis as it appeared in the 
dataset generated in the absence of DG023. Crosslinked peptides were identified 
with 75% peptide confidence or greater, and 2.74% prophet FDR (spectra). Data 
analysis and figure preparation was performed using Scaffold 4[188]. 
 
Electrostatic potential calculation 
Structural models of ERAP1 domains II-IV (lacking domain I due to limits on 
number of atoms allowed) were prepared for analysis using PDB2PQR, which 
calculated atomic charges using AMBER force field[189]. The output of 
PDB2PQR was then input to the DelPhiForce webserver[190] to calculate 
pairwise electrostatic potential. Settings used were: pairwise interactions mode, 
Gaussian dielectric distribution method, 3.0 grids/Å, 0.2M salt concentration. To 
test the effect of substitution at position 528, computational mutagenesis was 
performed on existing structural models, using the respective residue rotamers 
found in the alternate ERAP1 crystal structure. 
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Statistics 
For SAXS analysis, radii-of-gyration are presented as means of each curve fit 
with the respective fit error plotted. Fitting of SAXS data with structural models 
used Χ2 to quantify goodness-of-fit as well as model/data ratios to qualitatively 
demonstrate residual deviation. For statistical analysis of EC50, sigmoidal curves 
were fit to eight concentrations of inhibitor, in triplicate. LogEC50, standard error 
of measurement, and number of points (24) from two experiments were analyzed 
for statistical significance using two-tailed ANOVA. 
 
Figure design 
Structural figures were prepared using Pymol[153]. Graphical data were 
prepared with Graphpad Prism 7.0c[152]. 
 
Data availability 
Crystal structures of ERAP1 bound to DG013 or DG014 are deposited in the 
wwPDB, PDB ID 6M8P or 6MGQ respectively, with corresponding X-ray 
diffraction datasets deposited as datasets 605 and 606, respectively, in the 
SBGrid Data Bank. 
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CHAPTER IV 
Conclusions and future directions 
 
Summary 
ERAP1 exhibits complex catalytic behavior which is necessary for its role 
within MHC-I antigen processing. This behavior includes diverse substrate 
sequence preferences, a preferred minimum substrate length, and allosteric 
activation within a monomeric enzyme. This work identified two specific small-
molecule inhibitors of ERAP1-catalyzed short substrate hydrolysis by library 
screening and counterscreening against the related enzymes ERAP2 and IRAP. 
An additional screen/counterscreen for activators of short substrate hydrolysis 
identified one ERAP1-specific compound which inhibits peptide hydrolysis by 
ERAP1. Two of these three hit compounds inhibited ERAP1 activity within cells, 
suggesting their possible utility within in vivo or ex vivo experiments to 
specifically target ERAP1. 
These compounds, along with previously developed inhibitors, were used as 
molecular probes to identify three modes of inhibition. A crucial parameter to 
delineate inhibitor classification is the effect of inhibitor binding on ERAP1 
conformational state. Using small-angle X-ray scattering, we observed that 
peptides and peptidomimetic inhibitors caused ERAP1 to adopt a closed 
 140 
 
conformation, converting from the open conformation which is favored in solution 
in the absence of inhibitor. For non-peptidomimetic inhibitors, the short-substrate 
hydrolysis activator also stabilized the closed form. In contrast, ERAP1 
maintained an open conformation in the presence of the two short-substrate 
inhibitors. Categorizing small-molecule binding sites broadly into “active site” or 
“non-active site” and comparing with the conformation state induced by binding 
separates the compounds tested into the three classes: active site closer 
(DG013, bestatin); allosteric site closer (compound 3), and (putatively) active site 
opener (compounds 1 and 2).  
The crystal structures of open and closed ERAP1 bound to peptidomimetic 
inhibitors DG014 and DG013 respectively identified a novel structural state of 
ERAP1. In this state the protein adopts a open conformation but with helix ‘4a’ 
(previously found to be unstructured in the open conformation[45, 64]) organized 
along one side of the active site. Comparison of these two new structures along 
with existing ERAP1 structures demonstrated that helix 4a must move after 
becoming ordered to fully engage the substrate. This new intermediate along the 
substrate-binding pathway introduces an additional step in substrate binding 
which should be included in future kinetic modeling. 
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Refinements to the ERAP1 catalytic model 
The observation of ERAP1 conformational equilibria in the presence of 
inhibitors, the intermediate step in substrate binding prior to enzyme closing, and 
measurements of ERAP allosteric activity all inform a more detailed mechanistic 
model of catalysis. I propose that helix 4a is initially stabilized when a compound 
binds the active site that contacts Asp435. This intermediate state may then 
convert to a closed conformation while helix 4a simultaneously rotates to engage 
the substrate P1 sidechain with Phe433. 
In cases where the substrate P1 sidechain does not favor interaction with the 
aromatic sidechain of Phe433, I predict that the reverse rate (ERAP1 opening 
and H4a rotating Phe433 away from the substrate) remains fast, and substrate 
may then dissociate. If substrate interaction with Phe433 is favored, however, the 
reverse rate slows and ERAP1 favors the closed state, permitting catalysis. 
Product release may be ordered, where the hydrolyzed amino acid exits the 
active site though a partially closed state due to loop motion at the interdomain 
interface, which would disengage Phe433 and the opening rate would then 
accelerate.  
Regarding ERAP1 peptidomimetic inhibitors, I propose that the approximately 
1000-fold weaker potency of bestatin relative to DG013 is due to the contribution 
of Asp435. As shown in Chapter III, bestatin does not contact Asp435 in PDB ID 
3MDJ, and so the rate of conversion to the closed state is much slower, which 
results in more dissociation events occurring. However, bestatin binding still 
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shifts the ERAP1 conformational equilibrium to the closed state as observed by 
SAXS (Figure 3.1a), and as is consistent with the previously observed 
polymorphism-specific potency of bestatin.[94] 
This model predicts that mutation of Asp435 would impair ERAP1-catalyzed 
hydrolysis of long peptide substrates (I predict dipeptide substrates are also 
unable to interact with Asp435). This position and surrounding ones are well 
conserved evolutionarily, with either glutamate or aspartate present across 
vertebrates (…D(D/E)VSY…). (Figure 3.6c) Mutagenesis and enzymology 
studies can test this prediction. 
I also observed that compound 3 binding favors the closed conformation. As 
the docking site for compound 3 is far from both Asp435 and the active site, I 
conclude that occupancy at this site independently contributes sufficient 
energetic stabilization of the closed conformation to shift the ERAP1 
conformational equilibrium to favor the closed state. Conformational rate change 
caused by allosteric site occupancy may not be equivalent to the effect from 
Asp435 engagement, as compound 3 is less potent than DG013. (Figure 3.18, 
compare d and e) Measurement of on- and off-rates for compound 3 by kinetic 
analysis would clarify the relative impact of Asp435 and the allosteric site as 
effectors of ERAP1 conformational change. 
Additional ERAP1 enzymatic activity experiments involving mixtures of 
compound 3 and DG013 could indicate if one site is dominant over the other. For 
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example, measurements of DG013 IC50 in the presence of saturating compound 
3 would test if both compounds may bind simultaneously. More potent IC50 in this 
condition would be consistent with increased energetic stability of the closed 
conformation, while less potent IC50 would suggest that ERAP1 simultaneously 
bound to DG013 and compound 3 has a faster opening rate than “DG013 alone”-
bound ERAP1. 
 
Inhibition via blocking enzyme conformation change 
It has not escaped my attention that, of the three ERAP1-specific compounds 
identified, none fall within the ‘active site closer’ category, which is populated by 
only peptidomimetic compounds thus far. Closed conformation stabilization was 
also observed when saturating concentrations of the peptide SIINFEKL was 
present, which presumably occupies the active site. This indicates that 
conformational dynamism between open and closed states occurs during 
catalysis. It is possible that a comparable conformational effect occurs during the 
catalytic cycle of other members of the oxytocinase subfamily and for the M1 
family altogether. 
The development of peptidomimetic inhibitors and other compounds designed 
as substrate mimics may be unable to yield highly specific compounds for any 
individual member of this family due to commonalities in substrate sequence 
preferences, especially between ERAP1 and IRAP[46]. Based on the data 
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presented in this work, I predict inhibitors developed in this manner would induce 
conformational closing at saturation. However, the identification of compounds 1 
and 2 as inhibitors that do not stabilize the closed conformation identifies a new 
class of inhibitory compounds that modulate ERAP1. It is possible that other non-
closing inhibitory compounds might demonstrate similar selectivity for other 
members of the M1 family of aminopeptidases. Investigation of the binding sites 
of compounds 1 and 2 would clarify the basis of their selectivity. 
The related M1 aminopeptidase IRAP has been the target of several efforts to 
develop small-molecule inhibitors. IRAP inhibition has been shown to improve 
memory in rodent models[191]. The IRAP inhibitors HA08[192], HFI-419[193], 
and an aryl sulfonamide compound 8[194] have been developed, optimized, and 
characterized, and work is ongoing to localize the binding sites of these 
compounds. Cocrystallization has not been successful in some cases such as 
HA08, wherein IRAP crystals do not form when the inhibitor is present in the drop 
(personal communication, A. Hallberg). I observed a comparable inhibition of 
ERAP1 crystallization in drops with compound 2 present.(data not shown), 
though failure to crystallize is not conclusive evidence of structural alteration. It is 
possible that these IRAP inhibitors stabilize an open conformation, and similar 
methods used to examine ERAP1 conformation would likely be useful in studying 
IRAP conformational states given the similarities of the two proteins. One 
possible complication is the difference in oligomeric state: ERAP1 is a monomer, 
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while IRAP forms stable homodimers. Domain motion might be more difficult to 
determine when the scattering particle has increased in size. 
 
Further scrutiny of ERAP1 helix 4a dynamics 
Helix 4a was determined in this work to transiently order in response to 
substrate binding. This is notable behavior among M1 aminopeptidases, where 
other crystallized family members have an ordered helix 4a despite substrate 
presence or conformational state. Further dissection of this flexibility in ERAP1 
would help to understand the mechanism of this first catalytic step. Techniques 
such as hydrogen-deuterium exchange (HDX) could be used to identify the 
lability of mainchain amide hydrogens, which may be used as a readout of 
secondary structure, testing whether helix 4a unravels, or if it maintains 
secondary structure but is untethered along the ERAP1 active site. This 
distinction would further clarify the energetics involved in the reaction 
mechanism. It would also identify the uncrystallized structures present within the 
open ERAP1 structural ensemble, which would assist rational inhibitor design to 
target these states. 
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ERAP1-specific inhibitors as immune response modulators 
ERAP1-specific compounds 2 and 3 inhibit ERAP1 activity within HeLa cells. 
Many more steps lie ahead to demonstrate an effect in vivo, but these 
compounds have potential as tools to temporally modulate antigen processing. 
The ramifications of this may be positive or negative. Previous studies using 
bestatin as an in vivo immune modulator yielded immunostimulatory effects[111-
113]. The effects of dose concentration, dose duration, dose timing (at 
homeostasis, during primary immune response, during contraction of immune 
response, during memory immune response), and mode of delivery (localized or 
systemic) may each contribute uniquely in the outcome of specific ERAP1 
inhibition. Additionally, the assessment of inhibition (changes in MHC-I 
peptidome, changes in specific or global T cell activation, general physiological 
criteria) and the timescale of this assessment (short- or long-term) may greatly 
impact conclusions regarding the efficacy and safety of ERAP1-specific 
inhibition. With these compounds available, I look forward to further investigation 
of their potential as immune modulators in the laboratory and in the clinic. 
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APPENDIX I 
Primary sequences of ERAP1 constructs used in this work 
 
Inserted sequences highlighted yellow 
Polymorphic site position 528 highlighted cyan 
 
ERAP1 allele II Δexon 10 loop 
MVFLPLKWSLAIMSFLLSSLLALLTVSTPSWCQSTEASPKRHHHHHHHHHHSD
ENLYFQGTPFPWNKIRLPEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTII
LHSHHLQISRATLRKGAGERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVI
HYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASF
SIKIRREPRHLAISNMPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKI
TKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQ
SGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTME
WWNDLWLNEGFAKFMEFVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPV
STPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNT
KNEDLWDSMASIGGGGVDVKTMMNTWTLQKGFPLITITVRGRNVHMKQEHYM
KGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVEWIKFNVGM
NGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIGKLSIEKALD
LSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLIDKQT
WTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDV
TLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDE
SFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHM
VMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFD
KIRVWLQSEKLER 
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ERAP1 allele IV, isoform 2 
MVFLPLKWSLAIMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRL
PEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGA
GERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKST
YRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPL
VKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKIN
QADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESA
LLFDAEKSSASSKLDITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFME
FVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDV
SYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDG
VKGMDGFCSRSQHSSSSSHWHQERVDVKTMMNTWTLQRGFPLITITVRGRNV
HMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVE
WIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIG
KLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRL
LRDLIDKQTWTDEGSVSERMLRSELLLLACVHNYQPCVQRAEGYFRKWKESN
GNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKE
KLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFEL
GSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIG
WMDKNFDKIRVWLQSEKLEHDPEADATGLERMLESRGPFEQKLISEEDLNMHT
EHHHHHH 
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ERAP1 allele II, isoform 1 
MVFLPLKWSLAIMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRL
PEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGA
GERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKST
YRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPL
VKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKIN
QADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESA
LLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFME
FVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDV
SYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDG
VKGMDGFCSRSQHSSSSSHWHQEGVDVKTMMNTWTLQKGFPLITITVRGRNV
HMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVE
WIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIG
KLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRL
LRDLIDKQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESN
GNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKE
KLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFEL
GSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIG
WMDKNFDKIRVWLQSEKLERMHHHHHH 
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ERAP1 allele III, isoform 1 
MVFLPLKWSLAIMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRL
PEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGA
GERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKST
YRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPL
VKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKIN
QADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESA
LLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFME
FVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDV
SYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDG
VKGMDGFCSRSQHSSSSSHWHQEGVDVKTMMNTWTLQRGFPLITITVRGRNV
HMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVE
WIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIG
KLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRL
LRDLIDKQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESN
GNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKE
KLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFEL
GSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIG
WMDKNFDKIRVWLQSEKLERMHHHHHH 
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APPENDIX II 
Structural formulas of small molecules used in this work 
 
 
Figure S2. ERAP1 inhibitors used in these studies.  Bestatin is a dipeptide analog commonly used as a 
nonspecific aminopeptidase inhibitor.  Leucinethiol is a metalloprotease inhibitor that reacts with active site metal 
ion.  The octamer peptide SIINFEKL is a model T cell epitope and has been characterized as an ERAP1 
substrate.  DG013 and DG014 and DG023 are peptidomimetic inhibitors (trimer, decamer, and unamer 
respectively) where the first peptide bond is replaced by a nonhydrolyzable tetragonal transition-state mimic 
phosphinic group.  DG023 also has an unnatural photocrosslinker amino acid (L-4-benzoyl-phenylalanine) as its 
C-terminus.  Compounds 2 and 3 were previously characterized as a highly specific inhibitors of ERAP1-
catalyzed peptide hydrolysis (in preparation) 
3 
DG014 
DG013 
LeuSH 
SIINFEKL 
peptide 
bestatin 
2 
DG023 
1 
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